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Abstract 
 Obesity is rising worldwide leading the increase of the risks of metabolic 
diseases such as type 2 diabetes, hypertension, and cardiovascular diseases. The 
causes of obesity is not simple because various environmental factors such as diet, 
sedentary time, even stress influence the development of obesity and obesity-
related diseases. Since, there are always “obesogenic environment” surrounding us, 
sustainable, and effective long-term strategies for control obesity is required. 
Currently, there are several interventions of obesity including lifestyle and habit 
modification, bariatric surgery, and pharmacotherapy with anti-obesity drugs. 
However, some of them have some limitations in terms of safety, and difficulty for 
durability. In this context, dietary foods has some benefits because their safety is 
proved through the historical long-term intake, and easy to maintain continuous 
intervention by daily intake.  
Recent findings show that epigenetic alteration can be induced by several 
dietary food components as well as various obesogenic environmental factors. 
Therefore, in perspectives of epigenetics, pharmacotherapy with natural epigenetic 
regulators or daily intake of natural epigenetic regulators enrich dietary food can be 
suggested for newly strategies for prevention or treatment of obesity.   
 Sulforaphane (SFN) is a natural compound enriched in daily intake 
available cruciferous vegetables such as broccoli sprout. There are many previous 
studies about the beneficial effect of SFN on various diseases including obesity and 
diabetes mellitus. In general, it is widely believed that these beneficial effects are 
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mainly attributed to the activation of nuclear factor E2-related factor 2 (Nrf2), 
thereby, SFN is frequently utilized as Nrf2 activating agent. However, there are 
some conflicting evidences about the role of Nrf2 in metabolic diseases. It 
indicates that it is required to investigate the role of Nrf2 in the beneficial effects of 
SFN on obesity and obesity-related metabolic diseases such as type 2 diabetes.  
SFN newly received attention as a natural histone deacetylase (HDAC) 
inhibitor beyond Nrf2 mechanism especially in cancer biology. However, there is 
few study identifying the role of SFN as a HDAC inhibitor in obesity and related 
metabolic diseases. Moreover, the selectivity of SFN on HDAC families is unclear 
even in cancer biology.    
Here, I utilized Nrf2-KO mice to determine whether the anti-obesity effect 
of SFN depends on Nrf2. I found that SFN suppressed high fat diet (HFD)-induced 
increases in body weight and improved insulin sensitivity in both Nrf2-WT and 
Nrf2-KO mice. These reduction was not due to alteration of food intake or lipid 
excretion. Therefore, to further investigate the mechanism of SFN, I examined the 
effect of SFN on lipid metabolism in each peripheral tissues such as white adipose 
tissue (WAT), liver, skeletal muscle, and brown adipose tissue (BAT) in high fat 
diet (HFD)-fed mice. As results, SFN induced the expression of lipases such as 
adipose triglyceride lipase (ATGL), and hormone sensitive lipase (HSL) in WAT 
resulting in the reduction of epididymal WAT weight and the increase of circulating 
fatty acids. SFN also promoted the consumption of fatty acids to produce energy by 
increasing the expression of either mitochondrial biogenesis-related proteins such 
as nuclear respiratory factor 1 (NRF1) in liver or mitochondrial fatty acid 
oxidation-related proteins such as peroxisome proliferator-activated receptor 
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(PPAR) families in skeletal muscle, thermogenesis-related proteins such as 
uncoupling protein 1 (UCP1) in BAT, which are mainly regulated by Peroxisome 
proliferator-activated receptor gamma coactivator 1α (PGC1α), a key protein in 
energy metabolism. For definite understanding of regulation of PGC1α by SFN, I 
investigated the regulatory mechanism of SFN against PGC1α. I found while there 
were no changes on the expression of transcription factors such as myocyte 
enhancer factor 2C (MEF2C), and cAMP-response element binding protein 
(CREB), SFN increased the transcription of PGC1α in oxidation-related organ such 
as liver, and skeletal muscle. However, SFN increased the global histone 
acetylation on histone H3 in skeletal muscle. Thereafter, I identified that SFN only 
selectively inhibited the HDAC8 activity rather than other classical HDAC 
isoforms in vitro, and there was no change on HDAC8 expression in skeletal 
muscle. To further examine the relevance between HDAC8 and PGC1α, I deleted 
HDAC8 with leti viral system in HeLa cell. I found that knockdown of HDAC8 
increased the PGC1α expression, and the increase of PGC1α by SFN disappeared 
in shHDAC8 HeLa cell compared to shCont HeLa cells.  
Overall, for the first time, I have demonstrated that SFN suppresses HFD-
induced obesity regulating PGC1α-mediated lipid metabolism in several peripheral 
tissues by inhibiting HDAC8 activity, which is independent of Nrf2 system 
unlikely previous premise. These observations imply that SFN has an advantages in 
sustainable, and long-term intervention effect for obesity through the daily intake 
of broccoli or pharmacotherapy with single natural compound in perspectives of 
epigenetic regulation over the lifetime. 
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Sulforaphane-mediated prevention of metabolic diseases: 





Incidence of obesity is increasing worldwide as a leading cause of many 
metabolic diseases such as type 2 diabetes, atherosclerosis, fatty liver, and 
hypertension. Obesity can arise from various environmental factors, so called 
obesogenic environmental factors. Therefore, the interventions of obesity 
considering such a diversity are very important for effective control against obesity 
and obesity-related metabolic disease.  
There are several interventions including lifestyle, habit modification, 
bariatric surgery, and pharmacotherapy for combating obesity. However, there are 
many studies supporting that epigenetic regulations such as DNA methylation, 
histone modification (acetylation, deacetylation, methylation) correlates the 
incidence of obesity, even in human subject as well as in vitro and in vivo models. 
Therefore, as there are recently growing recognitions that obesity is an epigenetic-
related disease, it is highlighted that all options of intervention require to be applied 
understanding the epigenetic regulation against obesity.   
Although there are several FDA-approved epigenetic regulators utilized in 
several diseases such as cancer, it is remained a concern about their safety. In this 
context, it is gradually interested in potent dietary epigenetic regulators such as 
sulforaphane (SFN), a natural HDAC inhibitor in intervention of epigenetic-related 
diseases.  
Here, I reviewed the overview of obesity and obesity-related metabolic 
diseases such as type 2 diabetes. And I focused the significant correlation between 
epigenetic regulations and the development of obesity and obesity-related 
metabolic diseases. Additionally, especially, I suggested SFN as a natural potent 
3 
dietary agents for prevention or treatment of obesity in perspectives of epigenetic 
regulator.  
Overall, although it is the beginning state, this review can suggest that a 
lot of natural potent epigenetic regulators including SFN may influence our 
epigenome toward resistance to obesity by applying to our daily diet.     
 
Key words: Epidemic obesity, obesogenic environment, metabolic diseases, obesity 
intervention, pharmacotherapy, epigenetic regulation, HDACi, SFN 
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1.1. Introduction  
 Obesity has been commonly defined as a state with excess fat 
accumulation in the body arising from imbalance between energy intake and 
expenditure (1, 2). Incidence of obesity has been gradually increased worldwide in 
both developed and developing countries (3). Obesity is a "disease", which needs 
to be prevented or treated, because it is a main contributor for the metabolic 
diseases such as diabetes mellitus, atherosclerosis, fatty liver, and hypertension (4, 
5). Not only ectopic lipid accumulation in non-adipose tissues but also various 
cytokines such as tumor necrosis factors (TNFα) or adipokines secreted by adipose 
tissue can contribute to the development of metabolic diseases (6, 7).  
 Since obesity is a main cause and driving factor of metabolic diseases, 
adequate intervention of obesity is able to control both obesity and other metabolic 
diseases (8). Pharmacotherapy, bariatric surgery, and lifestyle intervention are 
suggested as combating strategies of obesity (9-11). Especially, pharmacotherapy 
has received the attentions since it is relatively easy to approach. However, so far, 
there are only five anti-obesity drugs, which have been approved by Food and Drug 
Administration (FDA), including orlistat, lorcaserin, phentermine/topiramate, 
naltrexone/bupropion, and liraglutide (10). For decades, other anti-obesity drugs 
were withdrawn from the market due to their unacceptable side effects, such as 
heart failure and insomnia (12).  
For epidemic incidence of obesity, it is gradually received attention that 
numerous environmental factors such as diets and lifestyle can influence 
epigenome to form DNA methylation and histone acetylation/methylation, thereby, 
modulate the obesity and the metabolic disorders over the lifetime (13, 14). Thus, 
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several natural compounds which have anti-obesity effects such as resveratrol, 
epigallocatechin gallate (EGCG), SFN are gradually focused in terms of safety 
compounds, and epigenetic regulators (15-19).  
In this chapter, I introduce SFN as a potent preventive agent against 
obesity and metabolic diseases in perspective of epigenetic regulator. I covered the 
overview of obesity and metabolic diseases, the importance of epigenetic 
regulation in the development of these diseases, and the evidences supporting that 
epigenetic mechanism might be involved in the anti-obesity effect of SFN.  
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1.2. Overview of metabolic diseases 
 
1.2.1. Causes of metabolic diseases  
 It is well-known that obesity is caused by imbalance between energy 
intake and expenditure in the body (1, 2). The “obesogenic environment” has been 
described as the environmental conditions promoting the onset of obesity (20). 
Various environment factors such as nutrition, sedentary lifestyle, and eating habits 
can promote obesity by complicate mechanisms (21). Once the obese state is 
chronically maintained, it leads to metabolic diseases including type 2 diabetes and 
fatty liver diseases (4, 5). Thus, it is important to understand the obesogenic 
environmental factors for effective intervention of obesity and obesity-related 
metabolic diseases. 
 
1.2.2. Mechanistic understandings of current combating agents of 
obesity 
 Obesity and metabolic dysfunction were associated with inadequate 
accumulation of fat and imbalance of energy homeostasis. Therefore, the regulation 
of energy intake and expenditure is important strategy to control obesity and 
comorbidity with other metabolic disorders (22).  
 A century ago, energy expenditure-targeted anti-obesity drugs such as 
thyroid hormone preparations, and dinitrophenol were developed. These drugs 
increased basal metabolic rate, thereby, increase energy expenditure. Despite their 
high efficacy, they show adverse effects such as hyperthyroidism, overheating risk, 
and death (23). In next generation, most developed anti-obesity drugs targeted 
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energy intake. For examples, FDA approved orlistat as an only long-term treatment 
agent for obesity in 1999. Mechanism of orlistat is inhibition of lipid absorption 
from the intestine by inhibiting lipase activity as a peripheral action of regulation 
of energy intake (24). Several anti-obesity drugs have central action targeting 
hypothalamus which is a regulatory region of feeding behavior in the brain. For 
examples, sibutramine, a serotonin-norepinephrine reuptake inhibitor, developed in 
1997 and had recognized as a representative appetite suppressant until 2010. 
However, it was withdrawn from drug markets due to its severe adverse effects 
such as nausea, cardiovascular failures, and strokes. Similarly with sibutramine, 
other appetite suppressant drugs such as phentermine, diethylpropion, 
phendimetrazine, and benzphetamine approved by FDA only for short-term use due 
to their adverse effects (25). The main action of recently developed drugs are also 
reduction of food intake increasing satiety. These drugs are approved by FDA for 
chronic use because they have less side effects compared to previous developed 
appetite suppressants. Their efficacy and safety have been proved in several 
clinical studies. Lorcaserin activates a selective serotonin 2C (5-HT2C) receptor 
expressed in hypothalamus, of which mechanism is increase of satiety (26). As a 
combination therapy, phentermine/topiramate with phentemine (a 
sympathomimetic amine with anorectic effect) and topiramate (unknown 
mechanism), naltrexone/bupropion with naltrexone (an opioid antagonist with 
weight loss effect) and bupropion (an inhibitor of dopamine and norepinephrine 
reuptake with anorectic effect) shows lose weight effects in overweight and obese 
populations (27, 28). Liraglutide, a glucacon-like peptide-1 (GLP-1) receptor 
agonist, shows effective weight loss efficacy targeting both central nervous system 
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(CNS) and gut. The weight losing mechanism of liraglutide is increasing satiety 
and decreasing food intake by dual actions on CNS and gut (29). Anti-obesity 
pharmacotherapies with these developed drugs are able to play an important role in 
intervention of obesity with lifestyle modification and bariatric surgery for 
overweight and obese persons. Nevertheless, all they still needs to be applied 
carefully because long-term safety evaluations are not sufficient (30). In this 
context, recently, natural compounds have been suggested as alternative agents for 
controlling obesity and obesity-related metabolic diseases. Unlike synthetic drugs, 
these compounds such as resveratrol, EGCG, and SFN have fewer side effects, and 
beneficial preventive effects in chronic diseases including obesity (17-19). It has 
been well studied that natural compounds with anti-obesity effect also targets 
various mechanisms such as lipase inhibition, appetite suppression, expenditure 
stimulation, inhibition of adipocyte differentiation, and increase of lipolysis to 
reduce adipose tissue mass (31, 32). For examples, caffeine, EGCG in tea leaves 
showed inhibitory effect on pancreatic lipase activity, thereby, blocked the 
absorption of lipid in intestine (33, 34). Saponins, (−)-Hydroxycitric acid (HCA) 
from garcinia cambogia are natural appetite suppressants (35, 36). As a natural 
energy expenditure stimulants, caffeine, capsaicin, and green tea extracts are 
suggested (37). Moreover, there are many natural compounds to decrease adipocyte 
not only by inhibiting adipocyte differentiation (adipogenesis) but also by 
increasing lipolysis such as genistein, curcumin (38-41). 
 
1.2.3. Suggesting mechanism for the next generation of combating 
agents of obesity 
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 Considering the subsequent failure of anti-obesity drugs over the last 
decades, a new paradigm shift in the strategies against obesity is required for 
effective prevention or treatment of obesity with less safety issues. Recent studies 
newly have suggested that gut microbiota, circadian rhythm, and sleep can 
influence on obesity, type 2 diabetes, and fatty liver diseases (27, 28, 42, 43). 
Additionally, as many risk parameters of obesity are influenced by environmental 
factors, epigenetics has been received growing attentions as a novel target of anti-
obesity agents beyond cancer biology (13, 29, 44, 45). In the context of epigenetic 
regulations, RNA interference (RNAi) such as siRNA and microRNA can also play 
a key role in metabolic diseases suggesting RNAi-based therapy for obesity (46). 
Therefore, it is also required a new insight for these newly proposed mechanisms to 
control complex incidence of obesity. However, it is required whether targeting 




1.3. Epigenetic regulation & metabolic diseases 
 
1.3.1. Epigenetic regulation   
Chromatins are made of nucleosomes which are complex package 
including DNA, protein (histone and non-histone), and RNA. And histones are 
octamer proteins consisted of H2A, H2B, H3, and H4 for DNA packaging in 
nucleus contributing to nucleosome structure (47). Epigenetic regulation is the 
modulation of gene expression by changing DNA chromatin structure without 
changes on DNA own sequence. The epigenetic regulation contains the methylation 
on cytosine nucleotide in DNA sequence, post-translational modification of histone 
proteins, and non-coding RNAs like miRNA. Once the epigenetic alteration occurs 
on DNA or histones, accessibility of transcription factors becomes different due to 
change of DNA conformation. The epigenetic changes induce reversible, but 
heritable variations from gene expression of same DNA sequences (48, 49).  
It has been shown that epigenetic abnormality induces aberrant 
development or certain diseases such as cancer (50). Therefore, there are many 
clinical evidences supporting that epigenetic regulators can have therapeutic effect 
on certain diseases, especially cancer (24, 25, 30, 51). Among them, 5 drugs such 
as decitabine, azacytidine, vorinostat, romidepsin, and belinostar were already 
approved by FDA with their anti-cancer effects (48). As the prevalence of obesity 
is increasing over the past several decades, growing attentions are placed on the 
role of epigenetic regulation in obesity and obesity-related metabolic diseases such 
as diabetes. Several metabolic genes such as peroxisome proliferator-activated 
receptor gamma coactivator 1 α (PGC1α), retinoic acid receptor α (RARα), and 
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fatty acid-binding protein 4 (FABP4) are referred to “epiobesigenic genes”, which 
play roles in development of obesity modulated by epigenetic regulation (52).  
 
1.3.2. DNA methylation & metabolic diseases 
The most widely documented epigenetic modification is DNA 
methylation. The methylation is direct addition of a methyl group (-CH3) on 
cytosine nucleoside next to a guanine known as CpG site in DNA sequence. The 
methylation on CpG site is mainly mediated by methyltransferase (DNMT), which 
contains DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMTL. If the methyl 
group is transferred to CpG site in promoter of certain genes, transcription factors 
fail to bind to the promoter region and induces the transcriptional silence of those 
genes. Since inappropriate methylation on CpG site leads to diseases-associated 
gene expressions profile, recovering effects by DNA methylation inhibitors may be 
a therapeutic intervention in epigenetic-related diseases such as cancer, obesity, and 
so on (29).   
Many previous studies demonstrated that DNA methylation correlated 
with obesity. For examples, it has been reported that high-intensity exercise 
decreases methylation on the promoter of metabolic genes such as PGC-1α, and 
mitochondria transcription factor A (TFAM) resulting in alleviation of obesity (29). 
On the other hand, different types of diets (e.g. high fat diet) cause changes in DNA 
methylation leading to promotion of obesity (44, 53). The group with intervention 
for weight loss show differences the level of genome-wide methylation compared 
to the control group (54, 55). Additionally, the DNA methylation in promoter of 
several metabolic genes can affect metabolic effects in development of obesity and 
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type 2 diabetes. These metabolic genes include peroxisome proliferator-activated 
receptor α (PPARα) related to lipid metabolism (56), leptin, melanocortin 4 
receptor (MC4R), neuropeptide (NPY), and pro-opiomelanocortin (POMC) which 
are associated with appetite regulation (53, 57-59), interferon γ (IFNγ), and tumor 
necrosis factor α (TNFα) related to inflammation (60, 61), fatty acid synthase 
(FAS), and uncoupling protein 1 (UCP1) which are involved in lipogenesis and 
thermogenesis, respectively (62, 63). 
However, it seems to be lacked that the consistent evidences about the  
consistent CpG site associated with obesity to support the strong correlation 
between global DNA methylation and obesity (45). 
 
1.3.3. Histone modification & metabolic disease 
 Histones are major components of nucleosome structures and contain each 
2 proteins of H2A, H2B, H3, and H4. Histones have positive electric charges for 
binding to electrically negative charged DNA. Apart from methylation, histone 
modification is also important epigenetic regulation to control gene transcription by 
compacting or relaxing chromatin to less or more accessible to transcriptional 
machinery. The post-translational histone modification is mainly mediated by 
histone acetyltransferase (HAT) and histone deacetylase (HDAC). While HAT 
transfers acetyl group to lysine amino acid residues, HDAC removes acetyl group 
from acetyl-lysine (Ac-Lys), which make differences on electrostatic change 
inducing alteration of binding affinity between histone and DNA resulting in 
activation or repression of gene transcription (64).  
Especially, HDACs play central roles in the large range of epigenetic 
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regulation due to their various subtypes. Classical HDACs contain total 11 types 
except Class Ⅲ HDACs (sirtuins), which are distinguished from other classes 
because their action is not major in histone modification. 11 mammalian HDACs 
are divided into 4 classes; classⅠHDACs (HDACs 1, 2, 3, and 8), classⅡHDACs 
(HDACs 4, 5, 6, 7, 9, and 10), classⅣHDACs (HDAC 11) as their characteristics 
(65). 
HDACs play different roles and are expressed in different location at 
different extent even in the same class type. While classⅠHDACs (HDACs 1, 2, 3, 
and 8) were ubiquitously expressed in various tissues and located in the nucleus, 
classⅡHDACs (HDACs 4, 5, 6, 7, 9, and 10) were expressed in limited tissues and 
shuttled between the cytoplasm and nucleus. It is little known about ClassⅣHDAC 
(HDAC 11). On the other hands, ClassⅢ HDACs (SIRT 1-7) play a 
distinguishable role as nicotinamide adenine dinucleotide (NAD)+-dependent 
pathway. Therefore, classical HDACs have total 11 HDACs (HDAC1-11). Since 
the role of HDACs would be very different depending on tissues, it is necessary to 
consider tissue-specific roles of each HDACs (65).  
Previous studies provide evidences that abnormal histone modifications 
are associated with epidemic disease including cancer, immune diseases, and 
neurodegenerative diseases (23, 42, 66). Therefore, therapies based on 
understanding of histone modification such as using HDAC inhibitors (HDACi) 
may be a good therapeutic intervention in several complex diseases associated with 
epigenetics such as cancer.   
Some previous studies provided evidences that deacetylation by HDACs 
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in certain metabolic genes as well as global histone modification has relevance 
with metabolism (67). For examples, it was revealed that classⅡa HDACs (HDAC 
4,5, and 7) respond to glucagon or insulin as mediators of cAMP –activated protein 
kinase (AMPK) pathway and regulate glucose production in liver. In detail, 
classⅡa HDACs deacetylate and activate the transcription of gluconeogenesis-
related genes such as glucose 6-phosphatase (G6Pase), consequently result in 
hyperglycemia in diabetic mouse models (43). HDACs also play role in muscle 
differentiation. HDAC1 interacts with MyoD inhibiting MyoD-dependent 
transcription of muscle-specific genes such as muscle creatine kinase (MCK), and 
myosin heavy chain (MHC) in myocytes (68). On the other hand, HDAC4 and 5 
which are included in classⅡHDACs inhibit myocyte enhancer factor 2 (MEF2) 
activity in differentiating myocytes (69). Additionally, post-translational 
modification of histone by HDAC also affect the transcription of several metabolic 
genes such as brain-derived neurotrophic factor (BDNF), an depression-related 
neurotrophic factor gene (70), adiponectin, insulin, and glucose transporter 4 
(GLUT4) relate to glucose homeostasis (71-73), and glucocorticoid receptor (GR) 
involved in stress mechanism (74).    
 
1.3.4 Epigenetic regulators as potential metabolic therapeutics 
Since there are several previous studies support that epigenetic regulations 
including histone modification modulate various metabolic pathway in different 
organs such as liver, muscle, it is necessary to consider epigenetic regulation in 
intervention of obesity and obesity-related metabolic disease. For combating 
obesity, epigenetic regulators as well as lifestyle modification such as physical 
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activity, and diet restriction can change the epigenetic mechanism in daily life.   
For examples, the epigenetic regulators, compounds modulating 
epigenetic mechanisms, including DNMT inhibitors (DNMTi), and HDAC 
inhibitors (HDACi) have been developed. So far, total 5 epigenetic drugs including 
Vidaza (5-Azacytidine), and Dacogen (Decitabine) as DNMTi and 
suberanilohydroxamic acid (SAHA), Beleodaq (Belinostat), and Istodax 
(Romidepsin) as HDACi are approved by FDA. Moreover, other epidemic 
regulator candidates are continuously developed besides of these drugs. 5-
Azacytidine and decitabine are nucleoside (cytidine) analogs, thereby prevent 
DNMT action and DNA methylation by integrating to DNA instead of nucleoside 
for DNA synthesis. HDACi contain several categories including hydroxamates, and 
cyclic peptide depending on their structures. Suberanilohydroxamic acid (SAHA), 
the first FDA-approved HDACi as well as as belinostat is in hydroxamate category 
and a pan-inhibitor targeting both classⅠ, and classⅡHDACs. Romidepsin is in 
cyclic peptide category. Clinical trials are undergoing for these drugs and show 
good clinical results in certain diseases, especially cancer (48, 75). These drugs 
have been mainly focused in cancer biology. Since it has been recently reported 
that epigenetic mechanisms are also involved in obesity and obesity-mediated 
metabolic diseases, there are evidences providing that epigenetic regulators can 
also control obesity and obesity-mediated metabolic diseases (52).  
However, there are limitations due to the fact that they are all pan-
inhibitors which did not target specific CpG sites or specific HDAC isoforms. 
Therefore, it is necessary to further develop the inhibitors against selective HDAC 
isoforms for more effective prevention or therapy of epigenetic-related disease 
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including not only cancer but also obesity and its related diseases (76, 77).  
Several studies highlighted that natural compounds as well as nutrients, 
and diets also have epigenetic regulatory effect by modulating DNA methylation or 
histone modification. These support natural epigenetic regulators could be also 
helpful for prevention or therapy of epigenetic-related disease such as cancer, 
obesity, diabetes, and so on.  
For examples, a specific B vitamin such as folate, vitamin B-12 is a 
nutrient participated in DNA methylation process as a methyl donors (78). 
Therefore, deficiency of these nutrients during pregnancy influences fetal 
programming inducing aberrant development (79). Moreover, some of natural 
compounds including isoflavone such as genistein, and tea polyphenols such as 
epigallocatechin gallate (EGCG) also inhibit DNMT enzyme reducing DNA 
methylation in cancer-related genes such as retinoic acid receptor b (RARb), and 
reversion-inducing cysteine-rich protein with Kazal motifs (RECK) in cancer cells 
(80, 81). High fat diet (HFD) can also alter DNA methylation status on CpG site in 
melanocortin-4 (Mc4r) genes associated with body weight regulation compared to 
standard diet in vivo (58). EGCG also enhances HDAC activity suppressing the 
pro-inflammatory action of nuclear factor-kappa B (NF-κB) in obese subjects (82). 
Curcumin degrades HAT enzyme, especially p300/CREB-binding protein (CBP) 
attenuating HFD-induced obesity and insulin resistance-associated abnormalities 
including lipogenesis, and inflammatory responses (83). Some of natural 
compounds including SFN from broccoli, and diallyl sulfide from garlic can inhibit 
HDAC enzyme and increase histone acetylation exerting anti-cancer effects (84, 
85). Especially, many previous studies supported that inhibitory effect of SFN on 
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HDAC enzyme activity is identified even in human subjects as well as in vitro and 
in vivo (84, 86-89).   
1.4. SFN, as an epigenetic regulator   
 SFN, one of isothiocyanates, is plentiful in cruciferous vegetables, 
especially in broccoli sprouts. It is well known that SFN has beneficial effects on 
numerous diseases such as anti-cancer, anti-microbial effect, anti-oxidative effect, 
and neuroprotective effect (3, 90-92). In general, it is widely believed that SFN can 
exert the beneficial effects on various diseases via activation of nuclear factor E2-
related factor 2 (Nrf2) (93-97). Moreover, a lot of researches frequently have 
utilized SFN as a positive control or activating agent to investigate the Nrf2 
pathway (98-101).  
 Presently, however, it is increasing the supporting evidences that SFN 
served as a representative example of epigenetic regulator, especially HDACi (89). 
Several studies demonstrated that SFN has anti-cancer effect in colon and prostate 
cancer cells by inhibiting HDAC activity as a distinct mechanism from previous 
proposed other mechanism such as Nrf2 (86, 87). The inhibitory effect of SFN on 
HDAC enzyme triggers the suppression of tumor growth in xenograft model and 
decreases in spontaneous intestinal polyps increasing global histone acetylation in 
colon and intestine in Apcmin mice model (84, 88). These observations indicate that 
a role of SFN as a HDAC inhibitor is available in vivo. Additionally, intake of 
SFN-rich broccoli sprouts induced inhibition of HDAC activity in peripheral blood 
mononuclear cells (PBMCs) of all human subjects in study (88). These findings 
supported that dietary intake of SFN-rich broccoli sprouts can modulate epigenetic 
phenomena by inhibition of HDAC in daily life, which can be expected even at the 
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same dose of SAHA, a clinical HDAC inhibitor approved by FDA.     
 Previous findings showed the HDAC inhibitory effect of SFN in various 
models especially in cancer. Moreover, recent evidences suggest that epidemic 
regulation play a key role in obesity and metabolic disease as well as cancer. 
Therefore, I suppose that SFN can be a potent epigenetic regulator, as a natural 
HDACi, in epidemic-related development of obesity and obesity-related metabolic 








 As the prevalence of obesity is globally increasing, thereby, and the risk 
of metabolic disease is rising, adequate intervention is needed to reduce the 
increasing rate of obesity. Presently, lifestyle and behavior modification, bariatric 
surgery, pharmacokinetics are available interventions for overweight and obese 
persons. However, currently approved drugs have limitations in safety issues 
because of their adverse effects.  
 As growing epidemic obesity, obesity is recognized as not just gene-
driven but environment-driven diseases. Recent findings related to the relationship 
between epigenetic regulation and obesity implies that epigenetic regulators are 
expended to apply in various diseases such as obesity and obesity-related diseases, 
not just cancer. Therefore, epigenetic-based intervention of obesity will be helpful 
to respond for the influences from dynamic environmental factors. In this context, 
it is growing interests in the natural compounds including SFN in the field of 
obesity and obesity-related diseases, which have epigenetic modulation ability and 
relatively safe than synthetic drugs.  
 Here, I found that SFN suppresses high fat diet (HFD)-induced obesity 
promoting PGC1α transcription by specific inhibiting HDAC8 activity increasing 
global acetylation of histone H3 and histone H4 in skeletal muscle. These findings 
are distinct from Nrf2, a representative target of SFN, and interpreted in 
perspective of epigenetic regulation. Since there are evidences that the HDAC 
inhibition effect of SFN is also found even in human, SFN may be potentially 
strong anti-obesity agents as an epigenetic regulator, HDACi. Moreover, epigenetic 
regulatory effect of SFN also can be obtained from the intake of SFN-enrich 
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dietary food such as broccoli as well as pharmacotherapy with the intake of SFN as 
a single compound, which means the beneficial effect of SFN may be easily 




 Epigenetic-based therapy for obesity and obesity-related metabolic 
diseases are novel approaches to consider dynamic environmental factors 
promoting onset of obesity. Thus, this approach may let us to unknown contributors 
in development of obesity and obesity-related metabolic diseases. However, 
previous researches on epigenetic therapy have limitation in terms of non-
specificity of the most epigenetic regulators. While epigenetic alteration is revealed 
as a hallmark of cancer, more evidences are needed to strongly confirm the 
relationship with epigenetic regulation and obesity. Therefore, further investigation 
of various natural epigenetic regulators and their precise mechanisms will extend 
our knowledge on the epigenetic therapies for obesity and obesity-related 
metabolic diseases. And it is required to investigate more for understanding 
complexity of epigenetic regulation in obesity and obesity-related metabolic 
diseases, and newly developing next generative epigenetic regulators considering 
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Sulforaphane suppresses high fat diet-induced obesity 





 Previous evidences about the beneficial role of SFN underlying nuclear 
factor E2-related factor 2 (Nrf2) mechanism in various disease such as cancer, and 
neuro degenerative diseases are now in question at least in obesity and obesity-
related diseases such as type 2 diabetes. It has been reported that SFN has the anti-
obesity effects in vitro and in vitro. However, since conflicting results on the role 
of Nrf2 in obesity between the researches with Nrf2 activator such as 1[2-cyano-
3,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-imidazole) and Nrf2 
loss-of function studies were reported, it is now necessary to review the role of 
Nrf2 in the anti-obesity effect of SFN to understand exact mechanisms.  
 Herein, I investigated whether the anti-obesity effect of SFN is dependent 
on Nrf2 or not using Nrf2-wild type mice and Nrf2-knockdown mice model. As 
results, I found that SFN attenuated high fat diet (HFD)-induced body weight 
gaining in both Nrf2-WT and Nrf2-KO mice. Moreover, SFN also improved 
glucose tolerance and insulin sensitivity in both mouse genotypes, which was 
referred from the results of OGTT, ITT, and HOMA-IR index. I also found that 
this beneficial effects of SFN were not attributed to the reduction of food intake 
(kcal/day) or the increase of excretion of fecal lipids (mg/feces g dry weight). 
Collectively, I revealed that the beneficial effects of SFN on obesity and 
insulin resistance were still available in absence of Nrf2. This implies that 
another mechanism may be involved in SFN’s action in HFD-fed mice. 
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2.1. Introduction 
Recent reports have demonstrated that sulforaphane (SFN) alleviates 
obesity by inhibiting adipogenesis and promoting lipolysis (1-4). The transcription 
factor nuclear factor (erythroid-derived 2)-like 2, also known as Nrf2, is a well-
known target protein of SFN and has been noted to regulate lipid metabolism (5, 6). 
For example, Whitman et al. reported that Nrf2 modulated metabolic properties of 
skeletal muscle in streptozotocin-induced diabetic atrophy (7). Heme oxygenase-1, 
via Nrf2-mediataed transcription control, was shown to regulate cardiac 
mitochondrial biogenesis (8). Proteomic analysis of Nrf2 deficient transgenic mice 
revealed that Nrf2 plays an important role in the synthesis and metabolism of fatty 
acids and other lipids in the liver (5). The enzyme ATP-citrate lyase, responsible 
for acetyl-CoA production, was negatively regulated by Nrf2, suggesting that Nrf2 
might be a major regulator of cellular lipid disposition in the liver (5). 
NAD(P)H:quinone oxidoreductase 1, one of the major Nrf2-regulated proteins, was 
shown to reduce hypertrophy in 3T3-L1 adipocytes (9). Synthetic Nrf2 activators 
such as 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-
imidazole) and oltipraz, as well as several natural compounds activating Nrf2 such 
as carnosic acid, carnosol, and curcumin have been also shown to have anti-obesity 
effect in vitro and in vivo (5, 10-13). Therefore, it seems possible to assume that 
Nrf2 might be a molecular target of SFN to inhibit adipogenesis and promote 
lipolysis.  
Although there are plentiful evidences to showing that Nrf2 activators can 
be developed as potent anti-obesity drugs, recent studies using genetically modified 
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Nrf2 knockout (KO) mouse model supports other role of Nrf2 in lipid metabolism 
(14-16). For example, deficiency in Nrf2 resulted in impaired adipogenesis and 
protected against diet-induced obesity (14). Nrf2-KO mice were partially protected 
from high fat diet (HFD)-induced obesity and developed a less insulin-resistant 
phenotype (16). Nrf2 deficiency improved glucose tolerance in mice fed a HFD 
(15). Nrf2 promoted the major proteins of adipogenesis such as CCAAT/enhancer-
binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ 
(PPARγ) by direct binding (3, 14, 17, 18). Moreover, Keap1-knockdown mice, 
which exhibit enhanced Nrf2 activity, increased markers of metabolic syndrome 
after long-term HFD feeding (19). Considering these conflicting evidences on the 
role of Nrf2 in lipid metabolism, a precarious assumption that Nrf2 might be a 
molecular target of SFN to inhibit adipogenesis and promote lipolysis needs to be 
re-viewed and clearly studied. 
 Therefore, I investigated the role of Nrf2 in the effect of SFN on HFD-fed 
Nrf2-wild type (WT) and Nrf2-KO mice. I found that the anti-obesity effects of 
SFN was shown in both HFD-fed Nrf2-WT and Nrf2-KO mice, suggesting that 
Nrf2, the well-known target proteins of SFN, was not involved in SFN-mediated 
anti-obesity effects. Moreover, I found that SFN improves insulin sensitivity in 
both HFD-fed Nrf2-WT and Nrf2-KO mice. These observations suggest that other 
mechanism than Nrf2 attributes to the anti-obesity effects of SFN. It is noteworthy 




2.2. Materials and Methods 
2.2.1. Animals 
C57BL/6J Nrf2-KO mice, originally developed by Prof. Masayuki 
Yamamoto (20), were obtained from RIKEN BRC (Tsukuba, Japan). The 
offsprings were genotyped as previously described (20). Primer pairs used in 
polymerase chain reaction (PCR) are listed in table 1. Mice were housed with free 
access to food and water in the animal facility of the Seoul National University in 
temperature-, light-, and humidity-controlled rooms with a 12-h light/dark cycle. 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee of Seoul National University (SNU-110126-8). 
Table 1. The primer sequences used for genotyping 
Gene Sequence 
NRF2-5'  
(sense for both genotype) 
5'-TGGACGGGACTATTGAAGGCTG-3' 
lac Z  
(antisense for LacZ) 
5'-GCGGATTGACCGTAATGGGATAGG-3' 
Nrf2-AS  




Age-matched male Nrf2-WT and Nrf2-KO mice (6-8 weeks old) were fed 
a chow diet (CD) or a high fat diet (HFD) (60 kcal% Fat, Research Diets, New 
Brunswick, NJ, USA) for 15 weeks. Mice were divided into three groups (n=6-7 
per group): (1) CD + phosphate-buffered saline (PBS) control group, (2) HFD + 
PBS group, and (3) HFD + SFN group. SFN (Santa Cruz Biotechnology, Santa 
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Cruz, CA, USA) was dissolved in PBS and orally administrated at doses of 50 
mg/kg body weight every day for 15 weeks.  
 
2.2.3. Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
Oral-GTT (OGTT) was performed by glucose oral administration (10% 
glucose, 10 ml/kg body weight) to Nrf2-WT and Nrf2-KO mice fasted for 16 hr. 
Blood glucose was measured from tail with Accu-Chek Blood glucose meter 
(Roche Diagnostics, Indianapolis, IN, USA) at 0, 15, 30, 60, and 120 min after 
glucose administration.  
ITT was carried out by intraperitoneal (i.p.) insulin injection (1 U/kg body 
weight) to Nrf2-WT and Nrf2-KO mice after fasting for 4 hr. Blood glucose was 
measured from tail with Accu-Chek Blood glucose meter at 0, 15, 30, 60, and 120 
min after injection of insulin. 
 
2.2.4. Serum biochemistry  
Blood samples were collected from tail with heparin capillary tube (Kent 
Scientific, Torrington, CT, USA) after 16 hr fasting. Fasting glucose was measured 
using an Accu-Chek Blood glucose meter and insulin level was analyzed using 
mouse insulin ELISA kit (ALPCO, Salem, NH, USA). Homeostasis model 
assessment-estimated insulin resistance (HOMA-IR) was calculated by the 
equation of [glucose (mg/dl) × insulin (ng/ml)]/405 with substitution of fasting 
glucose and insulin concentration values (21).  
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2.2.5. Food intake 
Food intake (g) per day was measured every week. Caloric intake was 
calculated by multiplying amount of food intake (g) by physiologic fuel value of 
CD or HFD, 3.85 kcal/g or 5.24 kcal/g, respectively.  
 
2.2.6. Lipid extraction and analysis of feces 
Collected feces were let dry overnight in fume hood and weighted as 
about 100 mg prior to more dry for 1 hr at 60℃ in oven. Each stools were 
extracted in 500 μl of folch solution [chloroform:methanol (2:1)] incubating at 
room temperature (RT) overnight. After incubation, each sample was spin down to 
pellet fecal debris at 12000 g RT. The supernatant was transferred and 500 μl 0.9% 
NaCl was added. It was shaken vigorously for 30 min and centrifuged at 12000 g 
RT to collect the organic (lower) phase. An aliquot of the organic phase was dried 
in fume hood overnight and dried lipid was dissolved in 25% Triton X-100 in 
ethanol. The content of fatty acids in feces was measured using HR series NEFA-
HR(2) kit (Wako Chemical, Richmond, VA, USA). 
 
2.2.7. Statistical analysis 
All data were expressed as the sample mean ± standard error of the mean 
(SEM). Statistical mean differences between groups were verified using Student’s 
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2.3.1. SFN suppresses HFD-induced increases in body weight in both 
Nrf2-WT and Nrf2-KO mice 
It has been reported that SFN has an anti-obesity effect (1, 2, 4). To 
investigate whether Nrf2 is involved in the anti-obesity effect of SFN, both Nrf2-
WT and Nrf2-KO mice were fed HFD for 15 weeks with or without SFN 50 mg/kg. 
Both HFD-fed WT and KO mice were obese up to 50.05% and 45.24%, 
respectively, compared to each control mice fed CD. I found that SFN significantly 
suppressed HFD-induced increase of body weight regardless of presence of Nrf2 
(Figure 1A and B). SFN significantly reduced the body weight gain in both Nrf2-
WT and Nrf2-KO (Figure 1C). I utilized Nrf2-WT and Nrf2-KO mice strains, 
which were verified before all experiments. The SV40 nuclear localization signal 
(NLS)-β-galactosidase-lacZ recombinant genes were inserted at the coding 
sequence of exon 5 in nrf2 in Nrf2 KO mice. Genomic DNA were extracted from 
mouse tails and amplified for genotyping PCR. I identified this insertion by 
decreased size of PCR band from 734 bp (WT) to 400 bp (KO) (Figure 1D).  
 
2.3.2. SFN improves HFD-induced impaired insulin sensitivity in both 
Nrf2-WT and Nrf2-KO mice 
Once feeding HFD continuously, obesity gets worse elevating 
accumulation of ectopic lipid in non-adipose tissues which consequently cause 
insulin resistance (22, 23). Since it has been reported that SFN relieved type 1 
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diabetes in streptozotocin-diabetic rats (24, 25), and SFN modulated glucose 
tolerance and insulin sensitivity in obese mice (26), I examined Nrf2 is involved in 
the SFN-mediated modulation. On 10 weeks after feeding of HFD with or without 
SFN (50 mg/kg), Nrf2 WT and KO mice were orally administrated 10% glucose 10 
ml/kg for oral-GTT (OGTT) and blood glucose level was measured in regular 
intervals (Figure 2A and B, respectively). After 2 weeks, i.p. of insulin 1 U/kg was 
performed in each mice for ITT and blood glucose level was measured in the same 
intervals as OGTT (Figure 3A and B). In both tests, as shown in graph curve of 
every interval and area under curve (AUC), which explains the total concentration 
of blood glucose level over time, HFD-fed mice significantly impaired glucose 
tolerance compared to CD-fed mice in both Nrf2 WT and KO mice (Figure 2AB 
and Figure 3AB). Blood glucose level of HFD and SFN-fed mice was recovered 
more effectively compared to HFD-fed mice (Figure 2AB and Figure 3AB). 
Consequently, SFN ameliorated insulin resistance in both Nrf2 WT and KO mice, 
at least in certain interval time.  
 
2.3.3. SFN improves HFD-induced increase in fasting glucose and 
fasting insulin resulting in improvement of HOMA-IR index in both 
Nrf2-WT and Nrf2-KO mice 
To verify the beneficial effect of SFN on insulin resistance, I analyzed the 
related parameters such as fasting glucose and fasting insulin in blood plasma. 
HFD-fed mice showed the increased level of fasting glucose and fasting insulin 
compared to CD-fed mice. But HFD and SFN (50 mg/kg)-fed mice showed lower 
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level of fasting glucose and fasting insulin compared to HFD-fed mice in both 
Nrf2-WT and Nrf2-KO mice (Figure 4A and B). HOMA-IR value also showed that 
the value of HFD-fed mice was significantly increased than the value of CD-fed 
mice. The value of HFD and SFN (50 mg/kg)-fed mice was significantly decreased 
compared to that of HFD-fed mice in both Nrf2-WT and Nrf2-KO mice (Figure 
4C). Overall, SFN ameliorated insulin resistance and Nrf2 was not involved in the 
SFN-mediated modulation.  
 
2.3.4. The anti-obesity effect of SFN is not attributed to decrease of food 
intake or increase of free fatty acid (FFA) excretion 
I examined whether SFN reduced the food intake or increased the lipid 
excretion in feces. Even though there were no differences of food intake between 
CD-fed group and HFD-fed group in both WT and KO mice, SFN rather increased 
the food intake of HFD-fed group in both WT and KO mice (Figure 5A). On the 
other hand, HFD decreased the FFA excretion to feces compared to CD in both 
WT and KO mice (Figure 5B). SFN and HFD-fed group showed similar excretion 
of FFA compared to HFD-fed group in both WT and KO mice (Figure 5B). 
Consequently, SFN increased food intake but did not influence on FFA excretion 
in both WT and KO mice. These observations suggest that the anti-obesity effect of 




2.4. Discussion  
Nrf2 has received attention as an important target protein in the 
mechanism of SFN’s activity for a long time. Since conflicting evidences on the 
role of Nrf2 in lipid metabolism including obesity have been reported, I 
investigated the role of Nrf2 in the anti-obesity effect of SFN. I found that SFN 
suppressed obesity and improved insulin resistance both in Nrf2-WT and Nrf2-KO 
mice. Consequently, the beneficial effects of SFN on obesity and insulin resistance 
were independent of Nrf2 (Figure 6).  
Chorley et al. discovered that SFN mainly modulated Nrf2 and Nrf2-
targeted genes, however, some gene groups which still bind to SFN regardless of 
Nrf2 are detected in ChIP-Seq analysis. Regulation of cell cycle, cholesterol 
biosynthesis, liver X receptor/retinoid X receptor (LXR/RXR) activation, aryl 
hydrocarbon receptor signaling, and cholesterol metabolism regulated by hormone 
receptor were included in those gene groups. Among them, cholesterol biosynthesis 
related 10 genes were outstandingly responsive to SFN (3). Therefore, they might 
be the potential molecular targets of SFN to modulate obesity and insulin resistance. 
Additionally, most previous in vitro and in vivo studies about the effect of SFN on 
obesity, have demonstrated that lipid metabolism related pathways including AMP-
activated protein kinase (AMPK)-mediated lipogenesis are meaningful signaling 
pathway for anti-obesity effect of SFN (1, 4). Moreover, as I mentioned in chapter 
1, because epigenetics has gradually taken center stage in epidemic obesity (27), it 
is assumed that epigenetic regulatory pathway is also possible mechanism of SFN’s 
action on obesity in terms that SFN is a dietary histone deacetylase (HDAC) 
inhibitor (28).   
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 In conclusion, I demonstrate that SFN relieved obesity and insulin 
resistance even without Nrf2. These results implicate that the action of SFN is not 
always accompanied by the activation of Nrf2 to show its beneficial effects, at least 
in obesity and insulin resistance. It is further required to elucidate the concrete 
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Figure 1. SFN suppresses HFD-induced increases in body weight gain in 
both Nrf2-WT and Nrf2-KO mice.  SFN (50 mg/kg) administrated group 
reduces body weight gain in HFD-fed Nrf2-WT mice (n= 20) (A). Lowering effect 
of SFN on body weight is still significant in HFD-fed Nrf2-KO mice (n=19) (B). 
“Black circles and straight lines = CD + vehicle; white circles and straight lines = 
HFD + vehicle; black triangles and dashed lines = HFD + SFN (50 mg/kg).” SFN 
also decreases HFD-induced body weight gain in both Nrf2-WT and Nrf2-KO 
mice (C). "Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars = 
HFD + SFN (50 mg/kg).” ## P < 0.01 vs. CD group mice, * P < 0.05 vs. HFD 
group mice. The genotyped PCR band size of Nrf2-KO mice (400 bp) (n=3) is 
smaller than one of Nrf2-WT mice (734 bp) (n=3). This is the representative band 
of amplified genomic DNA (D).  
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Figure 2. SFN improves glucose intolerance in both Nrf2-WT and Nrf2-
KO mice. SFN (50 mg/kg) treated group has lowering effect on blood glucose 
level compared to the level of HFD group in Nrf2-WT (n=20) (p= 0.05 in AUC) 
(A). SFN administrated group significantly decrease AUC of OGTT test compared 
to HFD group in Nrf2- KO mice (n=19), which means SFN recovers HFD-induced 
glucose intolerance (B). “Black circles and straight lines = CD + vehicle; white 
circles and straight lines = HFD + vehicle; black triangles and dashed lines = HFD 
+ SFN (50 mg/kg); Black bars = CD + vehicle; gray bars = HFD + vehicle; white 
bars = HFD + SFN (50 mg/kg).” Data represents the mean ± SEM. ## P<0.01 vs. 






Figure 3. SFN also improves insulin sensitivity in both Nrf2-WT and 
Nrf2-KO mice. SFN has a beneficial effect on insulin action in both Nrf2-WT 
(n=20) (A) SFN significantly decrease the glucose level at 30 min in Nrf2-KO 
mice (n=19) (B). “Black circles and straight lines = CD + vehicle; white circles and 
straight lines = HFD + vehicle; black triangles and dashed lines = HFD + SFN (50 
mg/kg); Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars = HFD 
+ SFN (50 mg/kg).” Data represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD 







Figure 4. SFN ameliorates HOMA-IR index reducing fasting glucose 
and insulin level in both Nrf2-WT and Nrf2-KO mice. SFN (50 mg/kg) 
treatment reduces fasting glucose in plasma of HFD-fed mice (A). Plasma insulin 
level in SFN administrated group was significantly decreased compared to the level 
of HFD group (B). HOMA-IR value indicates that HFD induces insulin resistance 
and SFN improves insulin sensitivity in Nrf2-WT (n=20) and Nrf2-KO-mice (n=19) 
(C) "Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars = HFD + 
SFN (50 mg/kg).” Data represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD 





Figure 5. SFN did not either decrease food intake or increase excretion 
of free fatty acid in feces. SFN (50 mg/kg) treatment rather increases food 
intake (kcal/day) compared to only HFD feeding (A). There are no significances in 
excretion of FFA in stool (mg/feces g dry weight) (B). These indicates that 
reduction of body weight by SFN is not due to decrease of food intake or increase 
of excretion of FFA in stool. “Black bars = CD + vehicle; gray bars = HFD + 
vehicle; white bars = HFD + SFN (50 mg/kg).” Data represents the mean ± SEM. 
## P<0.01 vs. CD group mice, **P<0.01 vs. HFD group mice.
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Figure 6. SFN suppresses HFD-induced obesity and improves insulin 
sensitivity independent of Nrf2 system. Summary. The beneficial action of 
SFN in HFD fed Nrf2-WT mice is remained even in HFD fed Nrf2-KO mice. This 
means that SFN attenuates HFD-induced obesity and insulin resistance in HFD-fed 











Sulforaphane enhances the lipase expression in white 
adipose tissue and PGC1α-mediated mitochondrial 




 Circulating fatty acids from plasma (released by lipolysis in adipose tissue) 
as well as lipids stored in each tissues are available to other oxidation-related 
tissues such as liver, skeletal muscle, brown adipose tissue as a fuel for ATP 
production. The metabolism of fatty acids including the fatty acid uptake and 
transport, lipogenesis for storage, fatty acid activation and β-oxidation is a 
complicate process regulated by multiple regulatory proteins in various tissues. 
Especially, PGC1α is a master regulator in fatty acid metabolism. PGC1α activates 
the mitochondrial mechanisms including mitochondrial biogenesis and oxidation 
binding with various transcription factors such as NRF1/2, PPAR families. Since 
the abnormality of lipid homeostasis in the body induces dyslipidemia, obesity, and 
obesity-related metabolic diseases such as type 2 diabetes, it is important to know 
the strategies for maintaining the lipid homeostasis.  
 Although there are some studies about anti-obesity effect of SFN, they are 
limited in terms that most of them have focused on the effect of SFN in adipose 
tissue. Therefore, for comprehensive understanding of anti-obesity effect of SFN, it 
is required to examine the systemic effect of SFN in various peripheral tissues.  
 Here, I investigated the effect of sulforaphane on lipid metabolism in 
various peripheral tissues such as white adipose tissue, liver, skeletal muscle, and 
brown adipose tissues to elucidate the underlying mechanisms of its anti-obesity 
effect. I found that SFN increased the expression of lipases including ATGL and 
HSL resulting in increase of circulating fatty acids. Simultaneously, I found that 
SFN also promoted the expression of several proteins involved in PGC1α-mediated 
mitochondrial biogenesis in the liver and mitochondrial oxidation in the skeletal 
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muscle, and brown adipose tissues. Overall, these observations demonstrate that 
SFN contributes the lipid homeostasis in peripheral tissues resulting in alleviative 
effect on obesity. 
 
Key words: Sulforaphane (SFN), Fatty acid metabolism. PPARγ coactivator 1- α 
(PGC1α), lipolysis, mitochondrial biogenesis, mitochondrial b-oxidation 
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3.1. Introduction 
Fatty acid metabolism involves most tissues, but adipose tissue, skeletal 
muscle and liver are quantitatively more important than others (1). Each of these 
tissues has a store of triacylglycerol that can be hydrolyzed (mobilized) to release 
fatty acids. In adipose tissue, these fatty acids may be released into the circulation 
for delivery to other tissues, whereas in the liver, muscle, and brown adipose tissue, 
they are a substrate for oxidation to produce ATP or heat (2-4).  
Fatty acid metabolism is tightly regulated by various proteins. Cluster of 
differentiation 36 (CD36, also known as fatty acid translocase), fatty acid binding 
proteins (FABPs), fatty acid transport proteins (FATPs) play roles in lipid uptake. 
Acyl-CoA synthetase long-chain family member 1 (ACSL1) involves in fatty acid 
activation which change in the form of long-chain acyl-CoA as a key intermediate 
formed in fatty acid metabolism (5). Fatty acid synthase (FAS) mediates fatty acid 
synthesis for storage (lipogenesis) (6). Adipose triglyceride lipase (ATGL) and 
hormone-sensitive lipase (HSL) regulate break-down of lipid for use (lipolysis) (7, 
8). Peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-
binding protein α (C/EBPα) modulate the differentiation of adipocytes 
(adipogenesis) (9). PPARγ coactivator 1- α (PGC1α) is a transcriptional coactivator 
found in most cells including skeletal muscle, which regulates the genes involved 
in fatty acid oxidation (10, 11). PGC1α tightly regulates mitochondrial biogenesis 
by interacting with various nuclear receptors such as nuclear respiratory factors 1/2 
(NRF1/2) or PPAR families including PPARα and PPARb/δ, promoting the 
expression of several enzymes related to generating ATP (10, 12). For examples, 
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carnitine palmitoyltransferase I (CPT-1) mediates fatty acids transportation across 
the outer mitochondrial membrane to promote fatty acid oxidation processes (13). 
Apart from PGC1α-mediated fatty acid oxidation, uncoupling protein (UCP) 
families including UCP1, 2, and 3 play a role mainly in uncoupled fatty acid 
oxidation which is the process using fatty acid for heat production (14).  
For the comprehensive understanding of its anti-obesity mechanism, I 
investigated the role of sulforaphane (SFN) in the white adipose tissue (WAT), 
brown adipose tissue, muscle, and liver of high fat diet (HFD)-fed mice. I found 
that SFN reduces the weight and size of adipocytes and enhances the expression of 
ATGL and HSL in WAT of HFD-fed mice. In the liver, SFN reduced fat 
accumulation, especially triglycerides. SFN increased the level of PGC1α, NRF1, 
and PPARα and enhanced mitochondrial biogenesis in the liver of HFD-fed mice. 
SFN increased the level of PGC1α in skeletal muscle as well. ACSL1, 
mitochondrial uncoupling protein 3 (UCP3), CPT-1, and PPARβ/δ were also 
increased by SFN in the skeletal muscle of HFD-fed mice. In the brown adipose 
tissue of HFD-fed mice, SFN increased the levels of PGC1α, NRF1, PPARβ/δ and 
UCP1. These observations suggest that the anti-obesity effect of SFN might be 
mediated by enhanced ATGL and HSL-induced lipolysis in WAT and PGC1α-




3.2. Materials and Methods 
3.2.1. Animals 
C57BL/6J male mice (6-8 weeks old) were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA). Mice were housed with free access to food 
and water in the animal facility of the Seoul National University in temperature-, 
light- , and humidity-controlled rooms with a 12-h light/dark cycle. All animal 
procedures were approved by the Institutional Animal Care and Use Committee of 
Seoul National University (SNU-110126-8). 
 
3.2.2. Treatment 
Age-matched male mice were fed a standard diet (STD) (10 kcal% Fat, 
Research Diets, New Brunswick, NJ, USA) or chow diet (CD) as a control, or a 
HFD (60 kcal% Fat, Research Diets). Mice were divided into three or four groups 
(n=6-9 per group): (1) STD (or CD) + phosphate-buffered saline (PBS) control 
group, (2) HFD + PBS group, and (3-4) HFD + SFN (10 or 50 mg/kg) group. SFN 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was dissolved in PBS and 
orally administrated every day for 8 weeks or 15 weeks.  
 
3.2.3. Pearson’s correlation study 
Pearson’s correlation study was used for evaluation of associations 
between variables. Statistical analyses were determined with the level of 
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significance at p < 0.05. Data were analyzed using GraphPad Prism (Version 4.03, 
GraphPad Software, San Diego, CA, USA).  
 
3.2.4. Tissue histology 
Epididymal WAT (eWAT) and liver were harvested and fixed with 4% 
formaldehyde in PBS solution. Each tissue was embedded in paraffin for sectioning 
and hematoxylin and eosin (H&E) staining, and examined at 200 X magnification. 
The average size and distribution of adipocytes in eWAT were measured using 
Image J (US National Institutes of Health, Bethesda, MA, USA).  
 
3.2.5. Serum biochemistry  
Serum non-esterified fatty acids (NEFA) were determined with a 
quantification assay kit (Wako Chemical, Richmond, VA, USA). Triglycerides in 
the serum were also examined with a serum triglyceride determination kit (Sigma, 
Saint Louis, MO, USA). Using spectrophotometer, the absorbance was measured at 
550 nm for NEFA and 540 nm for triglyceride. Total cholesterol and high-density 
lipoprotein (HDL) cholesterol were determined by using HDL-cholesterol kit 
(Asanpharm, Seoul, Korea). Low-density lipoprotein (LDL) cholesterol was 
calculated by Friedewald Formula of [Total cholesterol]-[HDL-cholesterol] - 
[Triglyceride/5] with substitution of each concentration value (mg/dL) (15).  
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3.2.6. Lipid extraction and analysis of liver 
Lipid accumulated in the liver was quantified by modified the "Folch" 
Procedure (16). Briefly, livers were weighted as about 100-150 mg and 
homogenized in 3 mM CaCl2. The homogenate (2.5 ml) was extracted with 10 ml 
of folch solution [chloroform:methanol (2:1)]. An aliquot of the organic phase was 
collected and dried in fume hood overnight. Dried lipid was dissolved in 25% 
Triton X-100 in ethanol. Hepatic triglyceride and total cholesterol were determined 
as described in Serum Biochemistry. 
 
3.2.7. Western blot assay  
Tissues were harvested and homogenized in radio immunoprecipitation 
assay buffer (RIPA buffer) (Cell signaling, Danvers, MA, USA) with one tablet of 
protease inhibitor cocktail (Roche, Penzberg, Germany). After centrifugation 
(14000 rpm, 10 min), the supernatants of homogenates were collected and analyzed 
to determine the concentration of proteins using protein assay kit (Bio-Rad, 
Hercules, CA, USA). The tissue lysates were subjected to 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a 
nitrocellulose membrane (GE healthcare, Piscataway, NJ, USA). The membrane 
was blocked with 5% skim milk and incubated with specific primary antibodies. 
Antibodies against ACSL1 (1:1000), NRF1 (1:1000), ATGL (1:1000), and HSL 
(1:1000) were obtained from Cell Signaling. Antibodies against PGC1α (1:1000) 
and UCP3 (1:1000) were purchased from Abcam (Cambridge, MA, USA). 
Antibodies against CPT1M (1:1000), PPARα (1:1000), PPARβ/δ (1:1000) and 
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UCP1 (1:1000) were obtained from Santa Cruz. Antibody against GAPDH was 
obtained from Sigma. After incubation with horseradish peroxidase-conjugated 
secondary antibodies (Sigma, 1:5000) for 1 hour at room temperature, the protein 
bands were visualized using a chemiluminescence detection kit (Amersham 
Pharmacia, Piscataway, NJ, USA). Band intensities were quantified with Image J. 
 
3.2.8. Quantitative real time-polymerase chain reaction (qRT-PCR) 
Tissues were homogenized in RNA iso plus (Takara, Dalian, China) and 
total RNA was isolated using the RNA Mini kit (Ambion, Foster City, CA, USA). 
cDNA was synthesized by PrimeScript RTase (Takara). Quantitative RT-PCR 
reaction was performed using CFX96 real-time PCR detection system (Bio-Rad). 
cDNA was amplified in the presence of SYBR Green (Bio-Rad). Relative 
expression levels of mRNA were calculated according to ddCt method (2-ddCt) (17). 
The primer sequences were described in table 1. 
Table 1. The primer sequences for qRT-PCR 






























































3.2.9. DNA isolation and mitochondrial DNA (mtDNA) content 
Tissues were homogenized in lysis buffer [100 mM Tris-HCl (pH 8.5), 5 
mM EDTA, 0.2 % SDS, 200 mM NaCl, and 100 μg/ml Proteinase K] and 
incubated overnight at 55oC in humidified condition. After isopropanol was added, 
the homogenates were shaken until DNA precipitates became visible. DNA pellets 
were washed with 70% Ethanol twice and dried for 10 minutes at room 
temperature. Isolated DNA pellets were dissolved in Tris-EDTA buffer. 
Quantification of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) was 
performed by quantitative RT-PCR reactions, using specific primers for the 
mtDNA encoded cytochrome B gene and the nDNA encoded 18S ribosomal RNA 
(rRNA) gene as described in Table 2. mtDNA copy number was determined as 
mtDNA/nDNA ratio, in which each value was calculated by using the formula: 2 × 
2 (∆CT) (18). 
Table 2. The primer sequences for nDNA and mtDNA 










3.2.10. Statistical analysis 
All data were expressed as the sample mean ± standard error of the mean 
(SEM). Statistical mean differences between groups were verified using Student’s 






3.3.1. SFN decreases the weight of eWAT and the size of adipocytes    
To elucidate the effects of SFN on eWAT, the weight of eWAT and the 
size of adipocytes were investigated in mice fed STD or HFD with or without SFN 
(10 and 50 mg/kg) for 8 weeks. As a representative adipose tissue, I compared the 
weight of eWAT among groups. Pearson’s correlation study was carried out to 
analyze the correlation between the body weight and the weight of eWAT altered 
by SFN. I found that SFN decreased the weight of eWAT (Figure 1A) and the 
reduction of body weight by SFN was strongly correlated with the decrease of 
eWAT weight by SFN (Figure 1B). On the other hand, H&E staining of eWAT 
showed that the adipocytes of eWAT in HFD-fed mice were larger than those in 
STD-fed mice. SFN treatment (10 or 50 mg/kg) significantly reduced the average 
size of adipocytes in the eWAT of HFD-fed mice (Figure 1C and D). Additionally, 
the number of adipocytes, which have cell surface area over 6000 mm2, was 
significantly less in eWAT of HFD + SFN (10 or 50 mg/kg) group, compared to 
HFD group (Figure 1E).  
 
3.3.2. SFN increases the expression of ATGL and HSL in eWAT   
To identify the mechanisms associated with SFN-mediated anti-obesitic changes in 
eWAT, I analyzed the genes regulating lipid metabolism in eWAT using Western 
blot analysis and qRT-PCR. I found that SFN treatment significantly increased the 
protein levels of ATGL and HSL, lipases involved in lipolysis in WAT (Figure 2A 
and B). Moreover, SFN treatment also significantly increased the mRNA 
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expression of Atgl and Hsl, consistent with the increased protein level (Figure 2C 
and D).  On the other hand, administration of SFN did not show significant 
change in other group genes including peroxisome proliferator-activated receptor γ 
(Pparγ), and CCAAT-enhancer-binding proteins α (C/epbpα) related to 
adipogenesis (differentiation of preadipocyte to adipocyte) and fatty acid synthase 
(Fasn or Fas) related lipogenesis (synthesis of lipid), cluster of differentiation 36 
(Cd36), and fatty acid binding protein 4 (Fabp4) related to fatty acid transport 
(lipid uptake into adipocytes) in WAT (Figure 2E). These results indicate that 
lipase-mediated lipolysis may contribute to the reduction of the weight of eWAT 
rather than other mechanisms in adipose tissue such as lipogenesis, adipogenesis. 
 
3.3.3. SFN changes lipid profile in serum 
Since SFN increased the expression of lipase in WAT in Figure 2, main 
action of SFN might not be limited just in WAT. Free fatty acid would be released 
to other organs such as liver, muscle, and brown adipose tissue, which are involved 
in lipid metabolism. Thus, I investigated how lipid factors in serum including 
NEFA level were changed by SFN. Consistently with increase of mRNA 
expression of lipase, NEFA, and glycerol level in serum of HFD+SFN 50 mg/kg 
group were significantly increased compared to HFD only fed group (Figure 3A 
and B). Additionally, administration of SFN also increased triacylglycerol (TG) 
level (Figure 3C). The level of total cholesterol, HDL and LDL cholesterol were 
significantly increased by feeding HFD but there are no significant difference 
between HFD only fed group and HFD+SFN 50 mg/kg group (Figure 3D-F).  
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3.3.4. SFN inhibits the fat accumulation in liver. 
From lipid profile in serum, SFN treatment increased the level of TG as 
well as NEFA. Since TG or cholesterol is synthesized from fatty acids in liver, I 
investigated the effect of SFN on lipid metabolism in liver. H&E data showed that 
HFD significantly increased the lipid droplet in liver. And HFD + SFN (10 or 50 
mg/kg) mice had less lipid droplet in liver compared to HFD-fed mice. This result 
indicated that administration of SFN inhibited the fat accumulation in liver (Figure 
4A). Additionally, I quantified the level of TG and cholesterol in liver. Although 
HFD did not increase the level of hepatic TG (mg/g) compared to STD, SFN (50 
mg/kg) treatment significantly reduced the level of hepatic TG than only HFD 
feeding (Figure 4B). On the other hand, there was no significant change in the level 
of hepatic cholesterol among STD, HFD, and HFD+SFN group (Figure 4C). These 
observations suggested that fatty acid released from adipose tissue to serum by 
SFN did not cause fat accumulation in liver. 
 
3.3.5. SFN increases the PGC1α-mediated mitochondrial biogenesis in 
liver. 
PGC1α a master regulator protein against mitochondrial biogenesis and 
mitochondrial oxidation, plays an important role in fatty acid metabolism in liver 
interacting with its coactivators such as NRF1, and PPARα, consequently resulting 
in induction of mitochondrial biogenesis or fatty acid oxidation (19). Thus, I 
examined the expression of not only PGC1αprotein but also its coactivators, 
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NRF1, and PPARprotein to elucidate the mechanism of reducing effect of 
SFN on lipid accumulation in liver. HFD significantly reduced the expression of 
PGC1αand SFN (10 or 50 mg/kg) treatment significantly recovered the 
expression of PGC1αFigure 5A and B). While HFD did not significantly 
change the expression of NRF1 compared to STD, SFN treatment (50 mg/kg) 
remarkably increased the NRF1 protein expression (Figure 5A and C). SFN (50 
mg/kg) administration also up-regulated the protein expression of PPARα reduced 
by HFD feeding (Figure 5A and D). Moreover, to more investigate whether the 
increase of mitochondrial biogenesis resulted from the remarkable up-regulated 
expression of PGC1α and NRF1 by SFN, I quantified mtDNA content. The 
mtDNA content was determined as relative expression of mitochondrial encoded 
gene such as cytochrome B normalized by the expression of nuclear encoded gene 
such as 18s ribosomal RNA. Although there was no significance between HFD fed 
mice and STD fed mice, HFD+SFN (10 or 50 mg/kg) fed mice significantly 
increased mtDNA content compared to HFD only fed mice (Figure 5E). These 
observations indicated that SFN increase the mitochondrial biogenesis up-
regulating the expression of PGC1α and its co-activators, followed by fatty acid 
oxidation in liver.  
 
3.3.6. SFN does not affect gene expressions in other lipid metabolic 
pathway in liver: lipid uptake, lipid transportation, lipid biosynthesis. 
To examine the effect of SFN in other lipid metabolic gene expression in 
liver, I carried out qPCR. However, I did not found any differences in the 
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expression of genes such as Pparγ, sterol regulatory element-binding protein 1c 
(Srebp1c), Fasn, stearoyl-CoA desaturase-1 (Scd-1), and diacylglycerol O-
acyltransferase 1 (Dgat-1) associated to biosynthesis of lipid and cholesterol. In 
addition, SFN (10 or 50 mg/kg) treatment did not change the expression of genes 
involved in fatty acid transport such as Cd36, fatty acid transport protein 5 (Fatp5), 
and fatty acid binding protein 1 (Fabp1), genes related to the synthesis of 
lipoprotein such as apolipoprotein B (ApoB), and microsomal triglyceride transfer 
protein (Mtp) (Figure 6A-C). Overall, these results suggested that reduction of fat 
accumulation in liver in HFD+SFN (10 or 50 mg/kg) fed mice observed in Figure 
5A is attributed not to decrease of lipid uptake or lipogenesis, increase of secretion 
of lipoprotein but to increase of the number of mitochondria with oxidation ability.  
 
3.3.7. SFN enhances PGC1α-mediated mitochondrial fatty acid 
oxidation in skeletal muscle.   
 Otherwise excess lipid factors in blood stream were appropriately 
removed, insulin resistance would get worse resulting in increasing the risk of 
certain metabolic disorders such as type 2 diabetes (20). So in order to elucidate 
where released free fatty acid (FFA) and TG to go and how they were eliminated, I 
next focused on muscle where fatty acid oxidation is mainly occurred because it is 
enrich mitochondria utilizing fatty acid as an energy source. As in liver, PGC1α 
modulates overall fatty acid oxidation by transcriptional activation of catabolic 
enzymes related to mitochondrial biogenesis and oxidation in serial action of other 
proteins such as ACSL1, UCP3, CP1-1M, PPARβ/δ in skeletal muscle (21, 22). 
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HFD decreased the expression of PGC1α compared to STD, and SFN (50 mg/kg) 
administration remarkably up-regulated the PGC1α expression (Figure 7A and B). 
While HFD significantly reduced the expression of ACSL1, a protein activating 
fatty acid to utilize for energy production, compared to CD, SFN (50 mg/kg) 
administration significantly increased the ACSL1 expression compared to HFD 
(Figure 7A and C). SFN (50 mg/kg) treatment also increased the expression of 
UCP3 slightly decreased by HFD, which is an important protein for catalyzing 
mitochondrial lipid oxidation (Figure 7A and D). Additionally, HFD feeding 
lowered the expression of CPT-1M, a protein involved in transportation of fatty 
acid from outer membrane of mitochondrial to inner membrane of mitochondria for 
oxidation, and SFN (50 mg/kg) administration recovered it (Figure 7E and F). SFN 
(50 mg/kg) administration also significantly increased the expression level of 
PPARβ/δ in HFD fed mice (Figure 7E and G). These results suggested that SFN 
enhanced PGC1αGC1t SFN fatty acid oxidation by up-regulation of oxidation-
related proteins expression. 
 
3.3.8. SFN enhances PGC1α-mediated thermogenesis in brown adipose 
tissue. 
Brown adipose tissue (BAT) as well as skeletal muscle is also oxidative 
organ for energy expenditure. As in liver and muscle, the expression of PGC1α, 
NRF1, PPARβ/δ protein was measured in BAT to elucidate the effect of SFN on 
mitochondrial biogenesis and fatty acid oxidation using western blot. Although 
HFD slightly influenced the expression of proteins, administration of SFN (50 
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mg/kg) significantly increased the expression of PGC1α, NRF1, PPARβ/δ (Figure 
8A-D). Furthermore, in brown adipose tissue, fatty acids are utilized in 
thermogenesis which is the process of heat production as an important component 
of the metabolic rate. Thus, I examined the expression of UCP1 as a representative 
marker protein of thermogenesis. Despite HFD did not change the UCP1 
expression, administration of SFN (50 mg/kg) increased the expression of UCP1 





 Imbalance between lipid uptake and release, synthesis and disposal can 
cause metabolic disorders as well as obesity (23). Various regulatory proteins are 
harmonized to control homeostasis of lipid metabolism depends on metabolic 
responses in each peripheral tissues. Firstly, adipose tissue is important to store 
lipid as an energy source. When we eat food, FFAs or TGs are absorbed from 
intestine. And they are transported in the form of chylomicron to adipose tissue. 
CD36 and FAPB4 mediated the uptake of fatty acids. Fatty acids are processed for 
lipogenesis and stored in the form of TG. Whenever our body needs energy, lipase 
such as ATGL, and HSL triggers TG to break down to FFAs. FFAs are released 
into blood (lipolysis) and transferred to other peripheral tissues such as liver, 
muscle, brown adipose tissue as sources of energy production (8). 
It has been reported that the mice lacking ATGL disrupted lipolysis and 
energy metabolism. Increase of ATGL expression promotes lipolysis and is helpful 
for reinforcing energy metabolism (20). Additionally, Some regulatory proteins 
involved in adipogenesis, and lipogenesis such as PPARγ, C/EBPα, FAS, are 
important key factors to keep balance between efflux and influx of lipid (24). 
Free fatty acids in blood are used for energy or participated in de novo 
synthesis of other lipid factors such as TG, and cholesterol in other organ. 
Secondly, liver is important to adjust TG and cholesterol metabolism (8). Liver 
takes up FFAs or TG through CD36, which is a membrane receptor. Lipogenesis-
related proteins such as PPARr, FAS, SCD1, DGAT1, and SREBP1c regulate de 
novo lipogenesis converting FFAs to TG or cholesterol. CPT-1a, and PPARα 
control the FFA oxidation in liver. PGC1α and its co-activator NRF1 mediate 
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mitochondrial biogenesis enhancing fatty acid oxidative metabolism in liver. In 
addition, liver secretes TG and cholesterol to blood stream in the form of 
lipoprotein such as very low-density lipoprotein (VLDL). In this process, 
lipoprotein synthesis-related proteins such as apoB, MTP mediate and pack TG, 
and cholesterol in the lipoproteins, which is secreted into the blood (20).  
Various lipid factors in blood such as FFA or TG can be used as a fuel 
source in muscle. Thirdly, muscle is important to burn fatty acids in mitochondria 
to produce energy as an ATP. Fatty acid oxidation in muscle usually contains a 
series of three steps (5). In first step, fatty acid is activated and transported into the 
mitochondria because enzymes involved in fatty acid oxidation are mainly located 
in mitochondrial matrix. Once fatty acids are taken up into the tissue, ACSL1 
catalyzes the activation of fatty acids to long-chain acyl-CoA, which is a pre-step 
for beta-oxidation (5). CPT-1 triggers transportation of fatty acids across the outer 
mitochondrial membrane in the form of acyl carnitine followed by next process to 
produce acetyl-CoA, an entry form for citric acid cycle, so called TCA cycle. 
Therefore, this step is regarded as a rate-limiting step in whole process of fatty acid 
oxidation (8). b-oxidation is a second step for fatty acids to be undergone after 
transportation inside the mitochondria. b-oxidation is the process by which fatty 
acid are broken down Acyl-CoA molecules in mitochondria followed by eventually 
enter into the TCA cycle in the form of acetyl-CoA. This step is prerequisite to 
next step. Electron transport chain is a final step in fatty acid oxidation to produce 
ATP as an energy source. During this process, UCP3, a downstream protein of 
PGC1α in mitochondrial inner membrane, exports the remaining fatty acid anions 
which are not oxidized and remained in mitochondria to the cytosol for recycling 
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them. This is allowed to maintain this fatty acid oxidation cycle continuously by 
reactivating fatty acids into acyl CoA rapidly in the first steps (25). PPARb/δ, and 
PGC1α, in nucleus, trigger and boost this fatty acid catabolism promoting 
transcription of fatty acid oxidative genes (24, 26-28). Moreover, PGC1α also 
promotes fatty acid catabolism by inncrease of mitochondrial biogenesis in 
addition to mitochondrial fatty acid oxidation, which is regulated by NRF-1, NRF2 
as co-activators in skeletal muscle.  
Brown adipose tissue as well as muscle is also one of oxidative organs 
contributing energy expenditure. Many oxidation-related proteins such as PGC1α, 
PPARb/δ, and NRF1 in muscle play similar roles in brown adipose tissue. 
However, thermogenesis mediated by UCP1 also occurred in brown adipose tissue 
as other consuming way of lipid source, which is an uncoupled oxidation 
accompanying a heat production rather than ATP production.   
 However, some gain-of function experiments suggested that PGC1α KO 
mice have normal mitochondrial volume in muscle and were rather lean. And these 
results seems to show that PGC1α is not required in mitochondrial biogenesis in 
vivo (21). Nevertheless, it is clear that obesity, diabetes and several metabolic 
disorders negatively correlate with the level of PGC1α (29, 30). And despite more 
research is required in role of PGC1α, the increase of PGC1α expression activates 
global mitochondrial function and consequently exerts metabolic benefits against 
obesity and other metabolic diseases (10).   
Consequently, SFN induced release of FFAs from adipose tissue to the 
blood stream by activating lipases such as ATGL, HSL. And administration of SFN 
induced the increase of TG level as well as FFA level in blood, which increase of 
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food intake might contribute. And then either FFA or TG was utilized as a fuel of 
energy metabolism in liver, muscle, and brown adipose tissue. PGC1α, ACSL1, 
CPT1, PPAR families, and UCP1 or 3 participated and mediated in stage by stage. 
Especially, the high level of FFA and TG (Figure 4A and C) indicated that SFN 
might accelerated fatty acid catabolism by promoting provision of lipid source 
from adipose tissue or perhaps intestine. In summary, SFN enhances fatty acid 
metabolism starting with PGC1 α in HFD-fed mice resulting in alleviation of 
obesity in Nrf2 pathway independent manner (Figure 9).  
In conclusion, I revealed more concrete mechanism of SFN via PGC1 α in 
each peripheral tissue such as adipose tissue, liver, and muscle in this chapter. 
However, the action of PGC1α is modulated by sequential multiple steps including 
transcription, translation, post-translation such as acetylation, ubiquitination and so 
on. Therefore, it is still remained how SFN regulated PGC1α resulting in beneficial 
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Figure 1. SFN reduces the size and weight of eWAT in HFD-fed mice. 
SFN reduced the weight of eWAT compared to HFD in a dose dependent manner. 
This was a modified data retrived from unpublished mastuer’s thesis. (Hee Yang. 
“Anti-obesity effect of sulforaphane through suppressing Ras activity in vitro and 
in vivo”. Master’s thesis, Seoul National University, 2010) (A). The reduction of 
body weight and decrease of eWAT weight by SFN (10 or 50 mg/kg) had positive 
correlation (B). “Black square = HFD; red circles = HFD + SFN 10 mg/kg; white 
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triangles = HFD + SFN 50 mg/kg.” H&E stained WAT (X200) histological data 
showed that size of adipocyte in adipose tissue of SFN group is similar to STD 
group (C). The average size of adipocytes in epididymal fat was also decreased by 
SFN (D). WAT of SFN treated group contained more small sized adipocytes 
(<6000 mm2) than big ones (> 6000 mm2) compared to only HFD fed group (E). 
Data represents the mean ± SEM. “Black straight line = STD + vehicle; Red 
straight line = HFD + vehicle; Dotted line = HFD + SFN 10 mg/kg; Broken line = 






Figure 2. SFN induces the expression of lipase such as ATGL, and HSL 
involved in lipolysis in epididymal WAT. Relative expression of ATGL (A) 
and HSL (B) proteins were suppressed by SFN (10 or 50 mg/kg) treatment in a 
dose dependent manner. SFN also up-regulated relative expression of Atgl gene (C) 
and Hsl gene (D) in HFD–fed mice. However, SFN had no significant effect on not 
only adipogenesis, lipogenesis related genes such as Pparγ, Cebpα, Fasn genes but 
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also Cd36, Fabp4 genes which were fatty acid transport related genes (E). “Black 
bars = CD + vehicle; gray bars = HFD + vehicle; white bars with horizontal stripe 
line = HFD + SFN 10 mg/kg; white bars = HFD + SFN 50 mg/kg.” Data represents 






Figure 3. SFN alters the lipid profiles in the blood serum. The level of 
NEFA (mmol/L) (A) and glycerol (μM) (B) were increased in blood serum by 
increase of lipolysis. The level of triglyceride (TG) (mg/dl) in blood serum 
HFD+SFN 50 mg/kg group was also increased compared to the level in blood 
serum of only HFD fed group (C). On the other hand, there were no significant 
changes in the level of total cholesterol (D), HDL-C (E), LDL-C (F). “Black bars = 
CD + vehicle; gray bars = HFD + vehicle; white bars = HFD + SFN 50 mg/kg.” 
Data represents the mean ± SEM. ## P<0.01 vs. CD group mice, **P<0.01, *P<0.05 




Figure 4. SFN lowers the accumulation of fat in liver. In histological 
picture, SFN decreased the accumulation of lipid in liver (A). SFN (50 mg/kg) 
administration remarkably decreased hepatic triglyceride compared to HFD (B). 
There was no significant difference in hepatic cholesterol among all groups (C). 
“Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars with horizontal 
stripe line = HFD + SFN 10 mg/kg; white bars = HFD + SFN 50 mg/kg.” Data 







Figure 5. SFN increases the expression of mitochondrial oxidation-
related proteins such as PGC1α, PPARα, and NRF1 in liver. SFN 
significantly increased mitochondrial oxidation-related proteins such as PGC1α (A, 
and B), PPARα (A, and C), NRF1 (A, and D). Administration of SFN (10 or 50 
mg/kg) increased the mitochondrial biogenesis described as the ratio of mtDNA to 
nDNA in a dose dependent manner (E). “Black bars = CD + vehicle; gray bars = 
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HFD + vehicle; white bars with horizontal stripe line = HFD + SFN 10 mg/kg; 
white bars = HFD + SFN 50 mg/kg.” Data represents the mean ± SEM. ## P<0.01, # 
P<0.05 vs. CD group mice, **P<0.01, *P<0.05 vs. HFD group mice. 
95 
96 
Figure 6. SFN does not have effects on the expression of other lipid 
metabolic genes of liver. SFN did not alter not only fatty acid and triglycerides 
biosynthesis-related genes such as Pparγ, Srebp1c, Fasn, Scd-1, and Dgat-1 (A) 
but also fatty acid uptake and transport-related genes such as Cd36, Fatp5, and 
Fabp1 (B), cholesterol biosynthesis-related genes such as ApoB, and Mtp (C). 
“Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars with horizontal 
stripe line = HFD + SFN 10 mg/kg; white bars = HFD + SFN 50 mg/kg.” Data 




Figure 7. SFN up-regulates the expression of proteins related to fatty 
acid oxidation in skeletal muscle. SFN (50 mg/kg) treatment significantly 
increased the relative expression of fatty acid oxidation related proteins such as 
PGC1α (A, and B), ACSl1 (A, and C), UCP3 (A, and D), PPARβ/δ (E, and F), and 
CPT-1M (E and G) in skeletal muscle. “Black bars = CD + vehicle; gray bars = 
HFD + vehicle; white bars with horizontal stripe line = HFD + SFN 10 mg/kg; 
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white bars = HFD + SFN 50 mg/kg.” Data represents the mean ± SEM. ## P<0.01, # 
P<0.05 vs. CD group mice, **P<0.01, *P<0.05 vs. HFD group mice.  
99 
 
Figure 8. SFN increases the expression of proteins related to 
mitochondrial fatty acid oxidation (PGC1α, NRF1, PPARβ/δ), and 
thermogenesis (UCP1) in brown adipose tissue. Administration of SFN (50 
mg/kg) significantly increased the protein expression of HFD-fed mice related to 
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mitochondrial fatty acid oxidation: PGC1α (A, and B), NRF1 (A, and C), and 
PPARβ/δ (A, and D). Moreover, SFN remarkably up-regulated the UCP1 
expression (A, and E). “Black bars = CD + vehicle; gray bars = HFD + vehicle; 
white bars = HFD + SFN 50 mg/kg.” Data represents the mean ± SEM. # P<0.05 vs. 




Figure 9. SFN enhances fatty acid metabolism in peripheral tissues. 
Summary. SFN promoted the lipase-mediated lipolysis in WAT simultaneously 
activating fatty acid oxidation in oxidative organs such as in the liver, muscle, and 
brown adipose tissue. Consequently, the lipid contents of WAT and liver were 
reduced by being used as a source of fatty acid oxidation in systemic oxidation 












Sulforaphane regulates the transcription of PGC1α 
by inhibiting HDAC8 activity  
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Abstract 
PGC1α, a key protein in energy metabolism, is regulated in multiple steps 
including the transcription, and post-translational modifications such as acetylation, 
phosphorylation. MEF2C, and CREB are major transcription factors of PGC1α. 
And besides of the transcription factors–mediated regulations, the epigenetic 
regulations such as DNA methylation by DNMT families, and histone modification 
by HDAC families also participate in the transcriptional regulation of PGC1α. 
Especially, recent findings provide evidences that the epigenetic alteration of 
PGC1α has the relevance in obesity, and obesity-related metabolic diseases such as 
type 2 diabetes (T2DM).  
On the one hands, the HDAC inhibition-mediated increase of histone 
acetylation by SFN has been investigated from in cell to human studies in cancer. 
However, there’s few study about the epigenetic regulatory effect of SFN in 
perspectives of obesity and obesity-related metabolic diseases. Moreover, even in 
cancer biology, there is a lack of studies about which certain isoform of HDACs 
has the preferences on the inhibition of SFN. 
Here, I found that SFN increased the mRNA expression of PGC1α in 
major oxidative tissues including skeletal muscle, and liver. However, there was no 
significant changes in the expression of transcription factors such as MEF2C, and 
CREB. Thereafter, to examine epigenetic regulatory effect of SFN, I investigated 
whether SFN increased the histone acetylation by inhibiting HDAC activity in 
HFD-induced obesity mice model. As results, I found that HFD with SFN 
administration remarkably increased the global acetylation of histone H3, and 
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histone H4 in skeletal muscle compared to HFD feeding. Moreover, I found that 
SFN selectively inhibited HDAC8 activity, belonged in the classⅠHDAC family, 
rather than other HDAC isoforms. Additionally, I revealed that the deletion of 
HDAC8 by lentiviral infection increased the expression of PGC1α in HeLa cell. 
Consequently, I concludes that SFN inhibits the HDAC8 activity, thereby, increase 
the transcription of PGC1α in HFD-induced obesity mice model. This mechanism 
may mainly contribute the anti-obesity effect of SFN. 
 
Key words: SFN, PGC1α, global histone acetylation, histone H3, histone H4, 





 Peroxisome proliferator-activated receptor gamma co-activator-1α 
(PGC1α) is a powerful regulator modulating energy metabolic program. PGC1α 
regulates oxidative phosphorylation as well as contents of mitochondria (1, 2). 
PGC1α activation is controlled through various regulatory circuits including post-
translational modification such as phosphorylation, acetylation, deacetylation, 
sumoylation, and methylation, in which various proteins such as AMP-activated 
protein kinase (AMPK), sirtuin1 (SIRT1), p38 mitogen-activated protein kinase 
(MAPK) were involved (3-7). In addition, PGC1α expression is also modulated by 
several transcription factors such as myocyte enhancing factor (MEF2C), cAMP 
response element-binding (CREB) depends on calcineurin A or 
calcium/calmodulin–dependent protein kinase (CaMK), respectively (8).  
 Besides of post-translational regulation or transcriptional regulation by 
transcription factors, it is well understood that epigenetic regulations such as DNA 
methylation or histone modification are also important regulatory mechanisms of 
PGC1α, which are mediated by DNA methyltransferase (DNMT) or histone 
deacetylase (HDAC) and histone acetyltransferase (HAT) (9, 10). For examples, 
the increase of methylation in PGC1α promoter occurred in T2DM patients and 
reduced the PGC1α expression compared to normal (10). Reversely, high-intensity 
exercise decreased the methylation in skeletal muscle-specific promoter of PGC1α 
controlling contraction of muscle (11). Additionally, it has been reported that 
trichostatin A (TSA) and valproic acid (VPA), as a representative HDAC inhibitors 
(HDACi) increased the PGC1α and PGC1α-related genes such as carnitine 
palmitoyltransferase 1 (CPT1) in neuroblastoma cells (12). Moreover, classⅡa 
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HDACs deacetylated MEF2 proteins suppressing MEF2-dependent transcription of 
PGC1α (9, 13). And pharmacokinetic specific inhibition of classⅠHDACs showed 
good mitochondrial signature and promoted oxidative metabolism in 
skeletalmuscle, in which PGC1α involved (14). However, it is less revealed that 
which specific HDAC isoforms play important roles in epigenetic regulation of 
PGC1α expression in terms of controlling metabolic disease including obesity.  
Recently, regulation of HDACs by dietary food component is suggested as 
a good strategy to control obesity (15). In chapter Ⅲ, I found that SFN increased 
PGC1α expression in oxidative peripheral tissues. However, intriguingly, recent 
previous studies demonstrate that SFN inhibits HDAC activity exerting anti-cancer 
effect (16, 17). But it is still unclear which isoform of HDACs is mainly involved 
in the action of SFN. Therefore, in this chapter, I examined how SFN regulates 
PGC1α expression considering SFN as a candidate for HDAC inhibitor. 
Consequently, although it is little known about the previous role of histone 
deacetylase 8 (HDAC8) in metabolism, I newly revealed that SFN increases the 
transcription level of PGC1α dependent HDAC8 using HDAC8 knockdown cell. 
Collectively, these results imply that the anti-obesity effect of SFN is explainable 




4.2. Materials and Methods 
4.2.1. Animals 
C57BL/6J WT mice (Male, 6-8 weeks old) were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA). Mice were housed with free access to food 
and water in the animal facility of the Seoul National University in temperature-, 
light-, and humidity-controlled rooms with a 12-h light/dark cycle. All animal 
procedures were approved by the Institutional Animal Care and Use Committee of 
Seoul National University (SNU-110126-8). 
 
4.2.2. HFD-induced obesity and sample administration 
Age-matched male mice were fed a standard diet (STD) (10 kcal% Fat, 
Research Diets, New Brunswick, NJ, USA) or chow diet (CD) as a control, or a 
HFD (60 kcal% Fat, Research Diets). Mice were divided into three or four groups 
(n=6-9 per group): (1) STD (or CD) + phosphate-buffered saline (PBS) control 
group, (2) HFD + PBS group, and (3-4) HFD + SFN (10 or 50 mg/kg) group. SFN 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was dissolved in PBS and 
orally administrated every day for 8 weeks or 15 weeks.  
 
4.2.3. Cell culture 
HeLa cell line was purchased from the American Type Culture Collection 
(ATCC) (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s 
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medium (DMEM) (Welgene, Korea) supplemented with 10% FBS (Sigma, St. 
Louis, MO, USA) and 1% Penicillin Streptomycin (Corning, Corning, NY, USA).  
 
4.2.4. Lentiviral infection 
Non-targeting shRNA (shCont), and shHDAC8 lentiviral particles were 
purchased from Santa Cruz (Dallas, TX, USA), 60% confluent HeLa cells were 
infected by each viral particles and incubated overnight. After incubation, cell 
culture medium was replaced with fresh DMEM for 24 hours. Selection of infected 
cells was done using puromycin (2 μg/mL) (Sigma, St. Louis, MO, USA) over 36 
hours. The final selected HeLa cells were utilized for further experiments. 
 
4.2.5. Western blot assay  
 Mouse tissues were harvested and homogenized in radio 
immunoprecipitation assay buffer (RIPA buffer) (Cell signaling, Danvers, MA, 
USA) with one tablet of protease inhibitor cocktail (Roche, Penzberg, Germany). 
After centrifugation (14000 rpm, 10 min), supernatant was collected and analyzed 
to determine the concentration of protein using protein assay kit (Bio-Rad, 
Hercules, CA, USA). Tissue lysates were subjected to 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose 
membrane (GE healthcare, Piscataway, NJ, USA). The membrane was blocked 
with 5% skim milk and incubated with specific primary antibody followed by 
horseradish peroxidase (HRP)-conjugated secondary antibody. The protein bands 
109 
were visualized using a chemiluminescence detection kit (Amersham Pharmacia, 
Piscataway, NJ, USA). Antibodies against CREB (1:1000) were obtained from Cell 
Signaling (Beverly, MA, USA). Antibody against MEF2C (1:1000), HDAC8 
(1:1000), and PGC1α (1:1000) were purchased from Abcam (Cambridge, MA, 
USA). Antibody against acetylated-histone H3 (1:1000) were attained from 
Millipore (Darmstadt, Germany). Antibody against histone H3 (1:1000), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:5000), b-actin (1:5000) 
were obtained from Sigma (St. Louis, MO, USA). Band intensity was quantified 
with Image J 
 
4.2.6. Quantitative real time poly chain reaction (qRT-PCR) 
Mouse tissues were homogenized in RNA iso plus (Takara, Dalian, China) 
and total RNA was isolated using the RNA Mini kit (Ambion, Foster City, CA, 
USA). cDNA was synthesized by PrimeScript RTase (Takara, Dalian, China). 
Quantitative RT-PCR reaction was performed using CFX96 real-time PCR 
detection system (Bio-Rad, Hercules, CA, USA). cDNA was amplified in the 
presence of SYBR Green (Bio-Rad). Relative expressions of mRNA level were 
calculated according to ddCt method (2-ddCt) (18). The primer sequences were 
described in table 1. 
Table 2. The primer sequences for qRT-PCR 



















4.2.7. HDAC activity assay 
 In vitro HDAC array was conducted by epigenetics profiling service 
(Reaction Biology, Malvern, PA, USA). Briefly, each HDAC (1-11) enzymes were 
pre-incubated with SFN and then substrate mixture (fluorogenic HDAC Substrate 
and co-factor) was added and incubate 2 hr at 30°C to initiate the reactions. To stop 
the reaction, developer with Trichostatin A was added. After generating fluorescent 
color, measure the kinetics at Ex/Em 360/460 nm for 1.5 hr with 15 min interval. 
 
4.2.8. Statistical Analysis 
All data were expressed as the sample means ± S.E.M. Statistical mean 
differences between groups were verified using Student’s t-test. Probability values 
of p < 0.05 and 0.01 were used as criterion for statistical significance.  
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4.3. Result 
4.3.1. SFN regulates PGC1α expression in transcriptional level in liver 
and skeletal muscle.     
To elucidate how SFN regulated PGC1α expression, I confirmed whether 
SFN had effect on mRNA expression of PGC1α using qPCR. In liver and skeletal 
muscle, HFD fed group outstandingly decreased the mRNA expression level of 
PGC1α up to about four fold compared to STD fed group. And Consistently with 
PGC1α protein expression in chapter 3, SFN 50 mg/kg significantly increased 
PGC1α mRNA expression both in liver and skeletal muscle (Figure 1A and B). 
Although HFD only fed group also significantly reduced PGC1α mRNA 
expression in white adipose tissue, HFD+SFN (10 or 50 mg/kg) group did not 
altered PGC1α mRNA expression compared to HFD fed group, unlike liver and 
skeletal muscle (Figure 1C). On the one hand, while SFN increased PGC1α protein 
expression level (Chapter 3, Figure 9A), there were no changes in PGC1α mRNA 
expression in brown adipose tissue of all groups (Figure 1D). Overall, SFN 
regulates PGC1α expression in transcriptional level in liver and skeletal muscle. 
Since PGC1α-mediated fatty acid oxidation (FAO) in these highly oxidative tissues 
mainly contribute to energy expenditure of whole body (2), transcriptional 
regulation might be a main mechanism of SFN to regulate PGC1α expression in 
HFD fed mice. On other hand, apart from liver and skeletal muscle, it needs to be 
further investigated that SFN might regulate PGC1α expression via another 
pathway such as post-translational modification in brown adipose tissue, which 
could influent on thermogenesis.   
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4.3.2. SFN did not affect the expression of transcription factors of 
PGC1α, MEF2C, and CREB proteins in skeletal muscle.  
 Because SFN increased the transcription of PGC1α, I identified the 
expression of transcription factors of PGC1α in skeletal muscle in which showed 
most outstanding increase of PGC1α. MEF2C and CREB are representative 
transcription factors binding to promoter of PGC1α (2). I found that the protein 
expression of MEF2C was not changed in all groups (Figure 2A and B). Although 
HFD slightly increased the protein expression of CREB compared to CD, SFN (50 
mg/kg) administration did not change the CREB expression compared to HFD 
(Figure 2A and C). These observations indicated that transcriptional regulation of 
PGC1α by SFN is not attributed to alteration of transcription factor expression 
level.     
 
4.3.3. SFN increased global histone acetylation in Skeletal Muscle. 
Besides of regulation by transcription factor such as MEF2C and CREB, 
PGC1α mRNA expression can be also controlled epigenetically (19, 20). Previous 
studies has been showed that SFN has an inhibitory effect on histone deacetylase 
(HDAC) activity resulting in some beneficial effects including anti-cancer effect 
(17, 21, 22). Thus, I investigated whether SFN affected the histone acetylation in 
skeletal muscle. HFD reduced the acetylation of histone H3 in skeletal muscle 
compared to CD. HFD + SFN (50 mg/kg) significantly recovered the acetylation 
of histone H3 reduced by HFD (Figure 3A-C). Consequently, SFN altered global 
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histone acetylation in skeletal muscle supporting that SFN had an effect on 
epigenetic regulation 
4.3.4. SFN specifically suppresses HDAC8 activity. 
Although some reports demonstrated that SFN inhibits total HDAC 
activity in various model (17, 23, 24), there are fewer evidences which specific 
isoform was affected by SFN. Thus, I conducted HDAC screening assay against 
HDAC isoforms (1-11) with SFN. The results showed that SFN only has specificity 
on HDAC8 enzyme belonged in class 1 HDAC having IC50 at 62.9 μM. On the 
other hand, SFN had no effect on other HDACs (Figure 4A). However, SFN did 
not reduce the expression of HDAC8 in skeletal muscle (Figure 5A and B). 
Therefore, these observations mean that SFN specifically inhibits HDAC8 enzyme 
activity resulting in epigenetic alteration.  
 
4.3.5. SFN increases the expression of PGC1α dependent on HDAC8. 
To further investigate whether the regulation of PGC1α by SFN depends 
on HDAC8 or not, I infected shRNA lentiviral particles into HeLa cells for deletion 
of HDAC8. Firstly, I compared HDAC8 HeLa cell with shCont HeLa cell against 
the expression of PGC1α to examine the relationship between PGC1α and HDAC8 
proteins. HDAC8 expression was knockdown (KD) in shHDAC8 HeLa cell 
compared to shCont HeLa cell. Reversely, PGC1α expression was up-regulated in 
shHDAC8 HeLa cell compared to shCont HeLa cell (Figure 6A). Consistently with 
protein expression, knockdown of HDAC8 significantly increased the mRNA 
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expression level of PGC1α about two folds compared to control (Figure 6B). 
Additionally, I investigated whether increase of PGC1α expression by SFN 
depends on HDAC8. I found that SFN (250 nM) increased the protein expression 
of PGC1α in shCont HeLa cell (Figure 6C). However, SFN did not change the 
protein expression of PGC1α in absence of HDAC8 (Figure 6C). Overall, HDAC8 





 As growing incidences of epidemic obesity worldwide due to various 
environmental factors, for last decade, the relevance of epigenetics on obesity has 
been received attentions (25-27). Epigenetic regulations are typically reversible 
without any change on DNA sequence itself and generally include DNA 
methylation, post-translational modification of histone proteins such as acetylation, 
deacetylation, methylation, and modification by small non-coding RNA (miRNA) 
(28).  
Many previous studies are focused on DNA methylation as an epigenetic 
marker. Some previous studies demonstrated that the addition of methyl groups on 
certain CpG sites (methylation) in several metabolic genes such as PGC1α is 
associated with the risk of obesity (29, 30). The level of methylation is different 
between groups with or without intervention for weight loss (31, 32). Nevertheless, 
summarized on most recent findings about the relationship between DNA 
methylation and obesity, systemic overview concluded that there is little consistent 
evidences for the relationship between global DNA methylation and obesity (20).  
Although there are relatively few studies about the relationship between 
histone modification and obesity, previous researches have showed that global 
histone modification associated with obesity (33, 34). In details, the acetylation or 
deacetylation of histone proteins by HAT or HDAC enzyme in several metabolic 
genes changes compactness of chromatin activating or repressing the expression of 
metabolic genes and appeared differently between normal state and disease-state 
like obesity (35, 36).  Recently, it is reported that several natural food 
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components such as curcumin, resveratrol, and epigallocatechin 3-gallate (EGCG) 
as well as diets, and nutrients act as a epigenetic modulator resulting in beneficial 
effects on metabolic system (15, 37). Especially, it is recently well understood that 
SFN acts as an inhibitor of histone deacetylase resulting in anti-cancer effects both 
in vitro and in vivo (16, 17, 38). Most of all, the inhibitory effect of SFN on HDAC 
activity is available even in the lower concentration of SFN compared to apoptosis 
and oxidative stress occurred in higher concentration of SFN in vitro (39). Thus, it 
is highlighted that epigenetic regulation of SFN might be more sensitive and 
primary mechanism than other mechanism of SFN. However, by so far, it is unclear 
that whether SFN has a beneficial effect on obesity and metabolic disorders 
through inhibitory activity of HDAC.  
Total mammalian classical HDACs are divided into 4 classes; 
classⅠHDACs (HDACs 1, 2, 3, and 8), classⅡHDACs (HDACs 4, 5, 6, 7, 9, and 
10), classⅣHDACs (HDAC 11) as their characteristics (40). Recently, previous 
study demonstrate that specific inhibitor of classⅠHDACs but not classⅡHDACs 
induce mitochondrial oxidative metabolism in skeletal muscle and adipose tissue 
supporting that inhibition of classⅠHDAC is more important to regulate energy 
metabolism (14). Although they suggested that HDAC3 belonged in 
classⅠHDACs is one of major contributors, deletion of HDAC3 showed partially 
mimic effect to the effect of classⅠHDACs specific inhibitor. Thus, the role of 
other HDACs belonged in classⅠHDACs including HDAC8 is required to be 
further explored.  
In this study, for the first time I found that HDAC8 as a specific novel 
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target of SFN, regulates PGC1α. HDAC8 is involved in class Ⅰ HDACs and is 
well known as a major epigenetic modulator in cancer, and other diseases (41). 
Moreover, HDAC8 specific inhibitor is received interests as an anti-cancer agent in 
clinical status (42). Here, I found that SFN, a natural compound from broccoli 
sprouts, inhibited specifically HDAC8 activity and sequentially it might induce 
histone acetylation and transcription of PGC1α (Figure 7).  
I found that SFN inhibit HDAC8 activity at IC50 62.9 μM in vitro. But it 
seems to be too high to have physiological relevance. However, it is possible to 
assume that in vitro HDAC enzyme activity screening system was deficient for 
physiological environmental co-factors including metal ions such as Co(Ⅱ) or 
Zn(Ⅱ), and monovalent cations such as Na+ or K+. Substrate binding affinity of 
HDAC8 is greatly influenced depends on the concentration of metal ions, and 
monovalent cations, which catalyzed HDAC8 activation (43, 44). Thus, binding 
affinity of SFN on HDAC8 enzyme might be higher in co-factor enrich 
physiological conditions. Secondly, previous study demonstrated that SFN usually 
metabolized to several metabolites such as SFN-glutathione-s-transferase (GSH), 
SFN-cysteine (Cys), and SFN-n-acetyl-l-cysteine (NAC). And they had higher 
binding affinity to HDAC enzyme than parent compound, SFN. It is because that 
their characteristics of structures is more favorable to bind with HDAC enzymes 
(39). Thus, SFN might more effectively inhibits HDAC8 activity in physiological 
body with synergistic effects of its metabolites.     
On the one hands, unlikely other HDACs in classⅠHDACs, HDAC8 also 
has non-histone substrates such as estrogen-related receptor α (ERRα), CREB 
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besides of histone proteins (45). Previous researches demonstrated that 
overexpression of HDAC8 reduces the phosphorylation of CREB and its activity 
suggesting that HDAC8 interact with CREB proteins, which is one of the 
transcription factor of PGC1α (46). Therefore, despite I already confirmed that 
expression of CREB was not changed in Figure 2, it is possible that SFN has also 
indirect mechanism through increase of CREB activity by inhibition of HDAC8.  
And it is necessary to interpret the observations found in this study more 
carefully, because it is not clearly defined yet histone deacetylase activity of 
HDAC8 between in vitro and in vivo because there are controversies (41). 
Consequently, I identified that SFN regulates the transcriptional regulation of 
PGC1α by inhibiting HDAC8 activity using HDAC8 KD cell model, but it needs to 
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Figure 1. SFN increases the mRNA expression of PGC1α in liver and skeletal 
muscle. SFN significantly up-regulated the relative Ppargc1a gene expression in 
liver (A) and muscle (B). However, SFN did not change the expression of 
Ppargc1a gene reduced by HFD in epididymal white adipose tissue (C). There 
were no significant differences among all groups in brown adipose tissue (D) 
“Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars with horizontal 
stripe line = HFD + SFN 10 mg/kg; white bars = HFD + SFN 50 mg/kg.” Data 
represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD group mice, **P<0.01, 




Figure 2. SFN does not alter the expression of transcription factor of PGC1α 
(MEF2C and CREB) in skeletal muscle. SFN (50 mg/kg) treatment did not 
increase the expression of MEF2C protein (A, and B). While HFD increased the 
expression of CREB protein, administration of SFN (50 mg/kg) did not change the 
expression (A, and C). “Black bars = CD + vehicle; gray bars = HFD + vehicle; 
white bars with horizontal stripe line = HFD + SFN 10 mg/kg; white bars = HFD + 




Figure 3. SFN acetylates histone H3 and H4 IN skeletal muscle. SFN (50 mg/kg) 
increased the acetylation of histone H3 (A and B) normalized with histone H3. 
“Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars with horizontal 
stripe line = HFD + SFN 10 mg/kg; white bars = HFD + SFN 50 mg/kg.” Data 
represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD group mice, **P<0.01, 




Figure 4. SFN specifically inhibits HDAC8 activity. Among 11 classical HDACs, 
SFN inhibited the activity of HDAC8 but not others. IC50 of SFN against HDAC8 
activity was 62.9 μM (A). Data represents the mean ± SD. “Black circles and 
straight line = HDAC1; white circles and dotted line = HDAC2; black triangles and 
dashed line = HDAC3; red triangles and broken line = HDAC8; black squares and 
dashed line = HDAC4; white squares and broken line = HDAC5; black diamonds 
and dashed line = HDAC7; white diamonds and straight line = HDAC9; black 
triangles and dotted line = HDAC6; white triangles and dashed line = HDAC10; 
black circles and broken line = HDAC11." SFN (50 mg/kg) treatment reduces 
HFD-increased the HDAC8 activity in skeletal muscle (B). “Black bars = CD + 
vehicle; gray bars = HFD + vehicle; white bars = HFD + SFN 50 mg/kg.” Data 
represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD group mice, **P<0.01, 




Figure 5. SFN does not decrease the expression of HDAC8 expression in 
skeletal muscle of HFD-fed mice. There were no significant differences against 
HDAC8 expression among all three groups, CD, HFD, and HFD+SFN (50 mg/kg). 
“Black bars = CD + vehicle; gray bars = HFD + vehicle; white bars = HFD + SFN 
50 mg/kg.” Data represents the mean ± SEM. ## P<0.01, # P<0.05 vs. CD group 




Figure 6. HDAC8 is involved in SFN-mediated increase in PGC1α expression. 
Knockdown of HDAC8 by infection of shRNA lenti viral particles induced an 
increase in PGC1α protein expression compared to control infected with non-
selected shRNA (A). Ppargc1a gene expression was also increased in HDAC8 
knockdown HeLa cell consistent to protein expression (B). While even 250 nM 
SFN treatment increased the mRNA expression of PGC1α, this effect was 
disappeared when HDAC8 expression was knockdown (C). “Black bars = Cont 
shRNA; white bars with diagonal line = HDAC8 shRNA.” Data represents the 




Figure 7. SFN regulates transcription of PGC1α by inhibiting HDAC8-
medated histone deacetylation. Summary. SFN suppressed the deacetylation of 















 In this study, I shed new light on the role of SFN as a natural epigenetic 
regulator in obesity beyond cancer biology. Moreover, for the first time, I 
suggested HDAC8 as a selective novel target of SFN to regulate PGC1α, a key 
protein in energy homeostasis.  
Summarized in chapter 1, I reviewed the obesogenic environment factors 
as complex causes of the development of obesity, thereby, highlighted the new 
insight about the importance of epigenetic-based therapy in obesity intervention. 
Most of all, I emphasized that the intake of dietary foods with epigenetic regulatory 
effect in daily life or dietary food-driven natural epigenetic regulator including 
sulforaphane (SFN) could be easily affordable strategies for controlling obesity 
especially in terms of safety, and sustainability..   
 Summarized in chapter 2, I investigated that the role of Nrf2 in anti-
obesity effect of SFN using genetically Nrf2 deleted mice. Opposite from the 
previous believes that most beneficial effects of SFN on various diseases were 
primarily due to Nrf2, anti-obesity effect of SFN was not depends on Nrf2 system. 
These observations indicate that Nrf2 is not involved in the anti-obesity effect of 
SFN, and other mechanism will play a major role in SFN’s action. 
 Summarized in chapter 3, thereafter, I examined the effect of SFN on lipid 
metabolism in various peripheral tissues such as white adipose tissue (WAT), liver, 
skeletal muscle, and brown adipose tissue (BAT). As a results, SFN up-regulated 
the expression of adipose triglyceride lipase (ATGL) and hormone sensitive lipase 
(HSL) in WAT, thereby, increased the level of circulating fatty acids and glycerol in 
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serum. Apart from WAT, SFN promoted peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC1α)-mediated fatty acid metabolism-related proteins 
expression. In liver, skeletal muscle, and BAT. In liver, SFN induced the 
mitochondrial biogenesis increasing the expression of nuclear respiratory factor 1 
(NRF1). Mitochondrial oxidation-related proteins such as acyl CoA synthetase 1 
(ACSL1), carnitine palmitoyltransferase I (CPT1), peroxisome proliferator-
activated receptorb/δ (PPARb/δ) were up-regulated by SFN in skeletal muscle. In 
BAT, SFN elevated the thermogenesis-related protein, uncoupling protein 1 (UCP1) 
as well as NRF1, and PPARb/δ. Collectively, SFN enhance the PGC1α-mediated 
lipid metabolism in each peripheral tissues resulting in reducing WAT weight, 
which is significantly correlated with reduction of body weight. 
 Finally, summarized in Chapter 4, I further investigate the regulatory 
mechanism of PGC1α by SFN for comprehensive understanding of SFN’s action in 
high fat diet (HFD)-fed mice. SFN remarkably increased the PGC1α expression in 
transcriptional level especially in liver and skeletal muscle. While the expression of 
PGC1α transcription factors such as myocyte enhancer factor 2C (MEF2C), and 
cAMP-response element binding protein (CREB) did not change, global 
acetylation on histone H3, and histone H4 were increased by SFN. With screening 
of SFN’s inhibitory effect against total 11 classical histone deacetylases (HDACs), 
I revealed that HDAC8, one of classⅠtype HDACs, is a novel, and selective target 
for SFN among HDACs families. Moreover, the relevance between HDAC8 and 
PGC1α is also uncovered in HDAC8 knockdown HeLa cell. Overall, I 
demonstrates that SFN regulated PGC1α, as a master regulator of energy 
homeostasis, in transcriptional level by selectively inhibiting HDAC8 activity.  
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Consequently, I conclude that SFN suppresses HFD-induced obesity and 
insulin resistance by regulating PGC1α-mediated mitochondrial biogenesis, 
oxidation, and thermogenesis in various peripheral tissues such as WAT, liver, 
skeletal muscle, BAT through selective inhibition of HDAC8 (Figure 1).  
These findings provide evidences supporting obesity intervention with 
natural epigenetic regulator such as SFN can be helpful and expected effective 
results. Therefore, it is required to discover various dietary food-driven natural 
epigenetic regulators besides of SFN. However, although epigenetics already has 
been widely studied in cancer biology, there is still limitation to application 
because most epigenetic regulators are “pan-inhibitors”, which target multiple 
isoforms, thereby, occurs unexpected side effects. Therefore, further investigation 
is needed to realize the next-generative epigenetic-therapy in personalized obesity 





Figure 1. The novel underlying mechanism of anti-obesity effect of SFN in 
HFD-fed mice. SFN inhibited HDAC8 activity resulting in promotion of PGC1α 
transcription in different way from Nrf2 mechanism. This is a novel mechanism, 
which mainly contributes the anti-obesity effect of SFN in HFD-fed mice. 
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국문 초록 
전세계적으로 비만 발병률이 증가함에 따라 비만으로 인한 제2
형 당뇨, 고혈압, 심혈관 질환 등 다양한 대사성질환의 위험이 높아지고 
있다. 이러한 비만의 원인은 단순하지 않고, 식이, 앉아있는 시간, 스트레
스 등 복잡 다양한 환경 요인들에 의해 비만 및 비만 관련 대사성질환이 
야기될 수 있다고 알려져 있다. 이와 같이 우리 주변에는 비만을 야기할 
수 있는 환경 요인들이 늘 존재하기 때문에, 효과적이고 장기적인 비만 
예방 및 치료 전략에 대한 필요성이 요구된다. 
비만을 중재하는 방법으로는 생활 습관 개선, 비만 치료 수술, 
비만치료제를 활용한 약물치료 등이 있다. 그런데 이 중 수술 또는 약물 
치료와 같이 일부 접근 방법들에 대해서는 부작용과 같은 안전성에 대한 
우려나 장기적으로 지속할 수 없다는 점에서 한계점이 존재한다. 이러한 
맥락에서, 식품은 오랫동안 먹어온 경험에 따라 안전성이 검증되고, 일상 
생활에서 지속적으로 섭취가 가능하다는 면에서 많은 이점이 있다고 할 
수 있다. 최근 연구결과들에 따르면, 우리 주변에 존재하는 비만을 야기
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할 수 있는 다양한 환경 요인들 뿐 아니라 우리가 일상적으로 섭취하는 
다양한 몇몇 식품들에 의해서도 후생학적 유전적인 변화를 일으킬 수 있
다고 보고되고 있다. 따라서 후생유전학적 관점에서 천연 조절성분들에 
의한 약물치료 또는 해당 성분이 풍부한 식품을 매일 섭취하는 것이 비
만을 예방 또는 치료하는데 있어 새로운 전략으로써 제시될 수 있다. 
설포라판은 매일 접할 수 있는 브로콜리와 같은 십자화과 식물
들에 풍부하게 들어있는 천연성분이다. 많은 연구들이 비만, 당뇨를 포함
하는 다양한 질환들에서 설포라판이 이로운 효과들을 가진다고 보고하고 
있다. 일반적으로 이러한 설포라판의 효과들은 대부분 Nrf2 단백질의 활
성을 통해 나타나는 것으로 알려져 있어, 다양한 논문들에서 SFN을 Nrf2 
활성화 작용제로서 빈번하게 사용하고 있다. 그러나 대사성질환에서는 
Nrf2의 상반된 역할에 대한 연구결과들이 보고됨에 따라 비만 및 제 2형 
당뇨 등 비만 관련 대사성 질환에서의 설포라판의 이로운 효과에 있어 
Nrf2의 역할에 대한 정확한 연구가 요구된다고 할 수 있다.    
최근 설포라판은 특히 암 생물학 분야에서 Nrf2 기작과 
별개로써 천연 HDAC 저해제로서 주목 받고 있다. 그러나 HDAC 
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저해제로서의 SFN에 대한 역할은 비만 및 관련 대사성질환에서는 거의 
연구된 바가 없다. 더욱이 암 생물학 분야에서 조차, 설포라판이 어느 
특정 HDAC에 대해 우선성을 가질지에 대해서는 불분명한 상태이다. 
본 연구에서는 Nrf2 KO 쥐를 사용하여 설포라판의 항비만 
효과에 대한 Nrf2 의존성을 연구하고자 하였다. 그 결과, 설포라판은 
Nrf2-WT과 Nrf2-KO 쥐 모두에서 체중 증가 억제 및 인슐린 감수성을 
개선하는 효과를 나타냄을 관찰할 수 있었다. 또한 이러한 감소는 식이 
섭취 및 지방 배출 변화에 따른 결과가 아님을 알 수 있었다. 
설포라판의 비만 억제 기작을 추가적으로 연구하기 위해 고지방식이를 
먹인 쥐의 백색지방, 간, 근육, 갈색 지방과 같은 다양한 말초조직에서의 
지방대사에 미치는 설포라판의 효과를 알아보고자 하였다. 그 결과, 
설포라판은 백색지방에서 ATGL, HSL과 같은 지방분해효소의 발현을 
증가시킴으로써 백색지방의 무게를 감소시키고 혈중 지방산 농도를 
올리는 것을 확인하였다. 또한, 설포라판은 에너지 생성을 위해 지방산 
소비 기작을 촉진시키는 것을 확인하였는데, 자세하게는 각 조직에서 
에너지 대사에서 주요한 역할을 하는 PGC1α 단백질 발현 증가와 함께 
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간에서 NRF1과 같은 미토콘드리아 생성 관련 단백질들의 발현 증가 및 
근육에서 PPAR 단백질들을 포함하는 미토콘드리아 지방산 연소 관련 
단백질들의 발현 증가, 갈색지방에서 UCP1과 같은 열발생을 통한 
지방산 연소 관련 단백질의 발현이 증가함을 확인하였다. SFN이 이러한 
PGC1α 를 어떻게 조절하는지 연구한 결과, 설포라판은 전사 
과정에서부터 PGC1α의 발현을 증가시키는 것을 알 수 있었고, MEF2C나 
CREB과 같은 전사인자들의 변화에는 설포라판이 영향을 미치지 않음을 
알 수 있었다. 그러나, 설포라판이 근육 조직에서 히스톤 단백질 H3, 
H4에서의 전체 아세틸레이션 정도를 증가시키는 것을 관찰함에 따라 
전형적인 HDAC들 중 SFN의 효과를 설명할 수 있는 특정 HDAC을 
조사하기 위해 11개의 HDAC 효소 저해 여부를 스크리닝하였다. 그 
결과, SFN은 선택적으로 HDAC8의 활성을 저해함을 알 수 있었다. 반면, 
설포라판은 근육 조직에서 HDAC8의 발현 변화에는 영향을 주지 않았다. 
HDAC8과 PGC1α 간의 상대적 관계에 대해 밝히기 위해 렌티 
바이러스를 활용한 HDAC8이 제거된 HeLa 세포를 만들어 사용하였으며, 
이를 통해 HDAC8이 제거됨에 따라 PGC1α의 발현 증가가 나타남을 알 
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수 있었고, 설포라판에 의해 PGC1α 발현이 증가하는 효과는 HDAC8이 
제거된 세포에서는 나타나지 않는 것을 관찰 함에 따라 설포라판의 
PGC1α 조절 기작은 HDAC8에 의존적임을 알 수 있었다.  
종합적으로, 본 연구에서는 처음으로 설포라판이 Nrf2와는 
비의존적인 작용 기전으로서 기존 관념과는 달리 새로운 타겟인 HDAC8 
저해를 통해 각 말초 조직에서 PGC1α로 매개되는 지방대사를 
조절함으로써 고지방식이로 유도된 비만을 억제하는 효과를 가짐을 
밝혔다. 이러한 연구 결과는 일상생활에서의 지속적인 브로콜리 섭취를 
통해서나 천연후성조절자로서의 설포라판 단일 성분을 활용한 새로운 
약물 치료 등의 방법으로 장기적으로 생애에 걸쳐 후생학적 조절을 통한 
비만을 중재를 할 수 있는 근거를 제시하였다는 점에서 의의를 가진다고 
할 수 있다.  
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